☰

Maria G. Castro, Ph.D. - Publications

Affiliations: 
University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
Gene Therapy, Glioma Therapy
Tree Info Grants Similar researchers PubMed Report error

399 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Faisal SM, Clewner JE, Stack B, Varela ML, Comba A, Abbud G, Motsch S, Castro MG, Lowenstein PR. Spatiotemporal Insights into Glioma Oncostream Dynamics: Unraveling Formation, Stability, and Disassembly Pathways. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). e2309796. PMID 38384234 DOI: 10.1002/advs.202309796  0.562
2023 Lowenstein PR, Castro MG. Combined cytotoxic and immune-stimulatory gene therapy for glioma - Authors' reply. The Lancet. Oncology. 24: e456. PMID 38039998 DOI: 10.1016/S1470-2045(23)00586-7  0.497
2023 Koschmann C, Al-Holou WN, Alonso MM, Anastas J, Bandopadhayay P, Barron T, Becher O, Cartaxo R, Castro MG, Chung C, Clausen M, Dang D, Doherty R, Duchatel R, Dun M, et al. A road map for the treatment of pediatric diffuse midline glioma. Cancer Cell. PMID 38039965 DOI: 10.1016/j.ccell.2023.11.002  0.454
2023 Umemura Y, Orringer D, Junck L, Varela ML, West MEJ, Faisal SM, Comba A, Heth J, Sagher O, Leung D, Mammoser A, Hervey-Jumper S, Zamler D, Yadav VN, Dunn P, ... ... Castro MG, et al. Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial. The Lancet. Oncology. 24: 1042-1052. PMID 37657463 DOI: 10.1016/S1470-2045(23)00347-9  0.539
2023 Faisal SM, Castro MG, Lowenstein PR. Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 37574780 DOI: 10.1016/j.ymthe.2023.08.009  0.565
2023 Garcia-Fabiani MB, Haase S, Banerjee K, McClellan B, Zhu Z, Mujeeb A, Li Y, Yu J, Kadiyala P, Taher A, Núñez FJ, Alghamri MS, Comba A, Mendez FM, Nicola Candia AJ, ... ... Castro MG, et al. H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Pediatric High-Grade Gliomas. Biorxiv : the Preprint Server For Biology. PMID 37398299 DOI: 10.1101/2023.06.13.544658  0.54
2023 Haase S, Lowenstein PR, Castro MG. "Sabotaging the Protein Factory to Overcome Glioma Stem Cell Resistance". Neuro-Oncology. PMID 37177889 DOI: 10.1093/neuonc/noad090  0.401
2023 Hollon T, Jiang C, Chowdury A, Nasir-Moin M, Kondepudi A, Aabedi A, Adapa A, Al-Holou W, Heth J, Sagher O, Lowenstein P, Castro M, Wadiura LI, Widhalm G, Neuschmelting V, et al. Artificial-intelligence-based molecular classification of diffuse gliomas using rapid, label-free optical imaging. Nature Medicine. PMID 36959422 DOI: 10.1038/s41591-023-02252-4  0.437
2023 Comba A, Varela ML, Faisal SM, Abel CC, Argento AE, Al-Holou WN, Hollon TC, Perelman JD, Dunn PJ, Motsch S, Castro MG, Lowenstein PR. Generation of 3D ex vivo mouse- and patient-derived glioma explant slice model for integration of confocal time-lapse imaging and spatial analysis. Star Protocols. 4: 102174. PMID 36930648 DOI: 10.1016/j.xpro.2023.102174  0.479
2023 Carney SV, Banerjee K, Mujeeb A, Zhu B, Haase S, Varela ML, Kadiyala P, Tronrud CE, Zhu Z, Mukherji D, Gorla P, Sun Y, Tagett R, Núñez FJ, Luo M, ... ... Castro MG, et al. Zinc Finger MYND-Type Containing 8 (ZMYND8) is epigenetically regulated in mutant Isocitrate Dehydrogenase 1 (IDH1) glioma to promote radioresistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36692427 DOI: 10.1158/1078-0432.CCR-22-1896  0.435
2023 McClellan BL, Haase S, Nunez FJ, Alghamri MS, Dabaja AA, Lowenstein PR, Castro MG. Impact of epigenetic reprogramming on antitumor immune responses in glioma. The Journal of Clinical Investigation. 133. PMID 36647827 DOI: 10.1172/JCI163450  0.495
2022 Varela ML, Comba A, Faisal SM, Argento A, Franson A, Barissi MN, Sachdev S, Castro MG, Lowenstein PR. Gene therapy for high grade glioma: the clinical experience. Expert Opinion On Biological Therapy. PMID 36510843 DOI: 10.1080/14712598.2022.2157718  0.499
2022 Faisal SM, Comba A, Varela ML, Argento AE, Brumley E, Abel C, Castro MG, Lowenstein PR. The complex interactions between the cellular and non-cellular components of the brain tumor microenvironmental landscape and their therapeutic implications. Frontiers in Oncology. 12: 1005069. PMID 36276147 DOI: 10.3389/fonc.2022.1005069  0.53
2022 Muthukrishnan SD, Kawaguchi R, Nair P, Prasad R, Qin Y, Johnson M, Wang Q, VanderVeer-Harris N, Pham A, Alvarado AG, Condro MC, Gao F, Gau R, Castro MG, Lowenstein PR, et al. P300 promotes tumor recurrence by regulating radiation-induced conversion of glioma stem cells to vascular-like cells. Nature Communications. 13: 6202. PMID 36261421 DOI: 10.1038/s41467-022-33943-0  0.512
2022 Franson A, McClellan BL, Varela ML, Comba A, Syed MF, Banerjee K, Zhu Z, Gonzalez N, Candolfi M, Lowenstein P, Castro MG. Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment. Frontiers in Medicine. 9: 966458. PMID 36186781 DOI: 10.3389/fmed.2022.966458  0.526
2022 Haase S, Banerjee K, Mujeeb AA, Hartlage CS, Nunez FM, Nuñez FJ, Alghamri MS, Kadiyala P, Carney S, Barissi M, Taher AW, Brumley EK, Thompson S, Dreyer JT, Alindogan CT, ... ... Castro MG, et al. H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models. The Journal of Clinical Investigation. PMID 36125896 DOI: 10.1172/JCI154229  0.465
2022 Comba A, Faisal SM, Dunn PJ, Argento AE, Hollon TC, Al-Holou WN, Varela ML, Zamler DB, Quass GL, Apostolides PF, Abel C, Brown CE, Kish PE, Kahana A, Kleer CG, ... ... Castro MG, et al. Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression. Nature Communications. 13: 3606. PMID 35750880 DOI: 10.1038/s41467-022-31340-1  0.542
2022 McClellan BL, Alghamri MS, Thalla R, Lowenstein PR, Castro MG. Murine brain tumor microenvironment immunophenotyping using mass cytometry. Star Protocols. 3: 101357. PMID 35634359 DOI: 10.1016/j.xpro.2022.101357  0.53
2022 Alghamri MS, Banerjee K, Mujeeb AA, Mauser A, Taher A, Thalla R, McClellan BL, Varela ML, Stamatovic SM, Martinez-Revollar G, Andjelkovic AV, Gregory JV, Kadiyala P, Calinescu A, Jiménez JA, ... ... Castro MG, et al. Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy. Acs Nano. PMID 35616289 DOI: 10.1021/acsnano.1c07492  0.548
2022 Messinger D, Harris MK, Cummings JR, Thomas C, Yang T, Sweha SR, Woo R, Siddaway R, Burkert M, Stallard S, Qin T, Mullan B, Siada R, Ravindran R, Niculcea M, ... ... Castro MG, et al. Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma. Neuro-Oncology. PMID 35605606 DOI: 10.1093/neuonc/noac141  0.507
2022 Qin T, Mullan B, Ravindran R, Messinger D, Siada R, Cummings JR, Harris M, Muruganand A, Pyaram K, Miklja Z, Reiber M, Garcia T, Tran D, Danussi C, Brosnan-Cashman J, ... ... Castro MG, et al. ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization. Cell Reports. 38: 110216. PMID 35021084 DOI: 10.1016/j.celrep.2021.110216  0.49
2021 Alghamri MS, McClellan BL, Avvari RP, Thalla R, Carney S, Hartlage MS, Haase S, Ventosa M, Taher A, Kamran N, Zhang L, Faisal SM, Núñez FJ, Garcia-Fabiani MB, Al-Holou WN, ... ... Castro MG, et al. G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy. Science Advances. 7: eabh3243. PMID 34586841 DOI: 10.1126/sciadv.abh3243  0.452
2021 Comba A, Faisal SM, Varela ML, Hollon T, Al-Holou WN, Umemura Y, Nunez FJ, Motsch S, Castro MG, Lowenstein PR. Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications. Frontiers in Oncology. 11: 703764. PMID 34422657 DOI: 10.3389/fonc.2021.703764  0.541
2021 Shah D, Comba A, Faisal SM, Kadiyala P, Baker GJ, Alghamri MS, Doherty R, Zamler D, Nuñez G, Castro MG, Lowenstein PR. A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1. Oncoimmunology. 10: 1939601. PMID 34249474 DOI: 10.1080/2162402X.2021.1939601  0.461
2021 Garcia-Fabiani MB, Haase S, Comba A, Carney S, McClellan B, Banerjee K, Alghamri MS, Syed F, Kadiyala P, Nunez FJ, Candolfi M, Asad A, Gonzalez N, Aikins ME, Schwendeman A, ... ... Castro MG, et al. Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies. Frontiers in Oncology. 11: 631037. PMID 34168976 DOI: 10.3389/fonc.2021.631037  0.554
2021 Alghamri MS, McClellan BL, Hartlage MS, Haase S, Faisal SM, Thalla R, Dabaja A, Banerjee K, Carney SV, Mujeeb AA, Olin MR, Moon JJ, Schwendeman A, Lowenstein PR, Castro MG. Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments. Frontiers in Pharmacology. 12: 680021. PMID 34084145 DOI: 10.3389/fphar.2021.680021  0.555
2021 Kadiyala P, Gregory JV, Lowenstein PR, Lahann J, Castro MG. Targeting gliomas with STAT3-silencing nanoparticles. Molecular & Cellular Oncology. 8: 1870647. PMID 33855166 DOI: 10.1080/23723556.2020.1870647  0.48
2021 Banerjee K, Núñez FJ, Haase S, McClellan BL, Faisal SM, Carney SV, Yu J, Alghamri MS, Asad AS, Candia AJN, Varela ML, Candolfi M, Lowenstein PR, Castro MG. Current Approaches for Glioma Gene Therapy and Virotherapy. Frontiers in Molecular Neuroscience. 14: 621831. PMID 33790740 DOI: 10.3389/fnmol.2021.621831  0.57
2020 Faisal SM, Mendez FM, Nunez F, Castro MG, Lowenstein PR. Immune-stimulatory (TK/Flt3L) gene therapy opens the door to a promising new treatment strategy against brainstem gliomas. Oncotarget. 11: 4607-4612. PMID 33400737 DOI: 10.18632/oncotarget.27834  0.553
2020 Nunez FM, Gauss JC, Mendez FM, Haase S, Lowenstein PR, Castro MG. Genetically Engineered Mouse Model of Brainstem High-Grade Glioma. Star Protocols. 1: 100165. PMID 33377059 DOI: 10.1016/j.xpro.2020.100165  0.493
2020 Haase S, Nuñez FM, Gauss JC, Thompson S, Brumley E, Lowenstein P, Castro MG. Hemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities. International Journal of Molecular Sciences. 21. PMID 33348922 DOI: 10.3390/ijms21249654  0.455
2020 Kadiyala P, Carney SV, Gauss JC, Garcia-Fabiani MB, Haase S, Alghamri MS, Núñez FJ, Liu Y, Yu M, Taher AW, Nunez FM, Li D, Edwards MB, Kleer CG, Appelman H, ... ... Castro MG, et al. Inhibition of 2-Hydroxyglutarate Elicits Metabolic-reprograming and Mutant IDH1 Glioma Immunity in Mice. The Journal of Clinical Investigation. PMID 33332283 DOI: 10.1172/JCI139542  0.494
2020 Gregory JV, Kadiyala P, Doherty R, Cadena M, Habeel S, Ruoslahti E, Lowenstein PR, Castro MG, Lahann J. Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. Nature Communications. 11: 5687. PMID 33173024 DOI: 10.1038/s41467-020-19225-7  0.513
2020 Garcia-Fabiani MB, Kadiyala P, Lowenstein PR, Castro MG. An Optimized Protocol for In Vivo Analysis of Tumor Cell Division in a Sleeping Beauty-Mediated Mouse Glioma Model. Star Protocols. 1. PMID 32984853 DOI: 10.1016/j.xpro.2020.100044  0.494
2020 Oliver CR, Westerhof TM, Castro MG, Merajver SD. Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography. Journal of Visualized Experiments : Jove. PMID 32865534 DOI: 10.3791/61654  0.381
2020 Sperry J, Condro MC, Guo L, Braas D, Vanderveer-Harris N, Kim KKO, Pope WB, Divakaruni AS, Lai A, Christofk H, Castro MG, Lowenstein PR, Le Belle JE, Kornblum HI. Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet Therapy. Iscience. 23: 101453. PMID 32861192 DOI: 10.1016/J.Isci.2020.101453  0.536
2020 Zhou W, Yao Y, Scott AJ, Wilder-Romans K, Dresser JJ, Werner CK, Sun H, Pratt D, Sajjakulnukit P, Zhao SG, Davis M, Nelson BS, Halbrook CJ, Zhang L, Gatto F, ... ... Castro MG, et al. Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. Nature Communications. 11: 3811. PMID 32732914 DOI: 10.1038/S41467-020-17512-X  0.493
2020 Alghamri MS, Thalla R, Avvari RP, Dabaja A, Taher A, Zhao L, Ulintz PJ, Castro MG, Lowenstein PR. Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1. Neuro-Oncology Advances. 2: vdaa042. PMID 32642696 DOI: 10.1093/noajnl/vdaa042  0.479
2020 Scheetz L, Kadiyala P, Sun X, Son S, Najafabadi AH, Aikins M, Lowenstein PR, Schwendeman A, Castro MG, Moon JJ. Synthetic high-density lipoprotein nanodiscs for personalized immunotherapy against gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32439701 DOI: 10.1158/1078-0432.Ccr-20-0341  0.557
2020 Comba A, Dunn PJ, Argento AE, Kadiyala P, Ventosa M, Patel P, Zamler DB, Nunez FJ, Zhao L, Castro MG, Lowenstein PR. Erratum: Fyn tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates antiglioma immune responses. Neuro-Oncology. PMID 32428217 DOI: 10.1093/Neuonc/Noaa063  0.598
2020 Garcia-Fabiani MB, Ventosa M, Comba A, Candolfi M, Nicola Candia AJ, Alghamri M, Kadiyala P, Carney S, Faisal SM, Schwendeman A, Moon JJ, Scheetz L, Lahann J, Mauser A, Lowenstein PR, ... Castro MG, et al. Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development. Expert Opinion On Investigational Drugs. PMID 32400216 DOI: 10.1080/13543784.2020.1768528  0.61
2020 Luo L, Guan X, Begum G, Ding D, Gayden J, Hasan N, Fiesler VM, Dodelson J, Kohanbash G, Hu B, Amankulor NM, Jia W, Castro MG, Sun B, Sun D. Blockade of cell volume regulatory protein NKCC1 increases TMZ-induced glioma apoptosis and reduces astrogliosis. Molecular Cancer Therapeutics. PMID 32393472 DOI: 10.1158/1535-7163.Mct-19-0910  0.455
2020 Comba A, Dunn PJ, Kish PE, Kadiyala P, Kahana A, Castro MG, Lowenstein PR. Laser Capture Microdissection of Glioma Subregions for Spatial and Molecular Characterization of Intratumoral Heterogeneity, Oncostreams, and Invasion. Journal of Visualized Experiments : Jove. PMID 32338655 DOI: 10.3791/60939  0.543
2020 Mendez F, Kadiyala P, Nunez FJ, Carney S, Nunez FM, Gauss JC, Ravindran R, Pawar S, Edwards M, Garcia-Fabiani MB, Haase S, Lowenstein PR, Castro MG. Therapeutic efficacy of immune stimulatory thymidine kinase and fms-like tyrosine kinase 3 ligand (TK/Flt3L) gene therapy in a mouse model of high grade brainstem glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32332014 DOI: 10.1158/1078-0432.Ccr-19-3714  0.562
2020 Scheetz LM, Yu M, Li D, Castro MG, Moon JJ, Schwendeman A. Synthetic HDL Nanoparticles Delivering Docetaxel and CpG for Chemoimmunotherapy of Colon Adenocarcinoma. International Journal of Molecular Sciences. 21. PMID 32150841 DOI: 10.3390/Ijms21051777  0.344
2020 Mendez FM, Núñez FJ, Garcia-Fabiani MB, Haase S, Carney S, Gauss JC, Becher OJ, Lowenstein PR, Castro MG. Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease. Neuro-Oncology. 22: 195-206. PMID 32078691 DOI: 10.1093/Neuonc/Noz218  0.513
2020 Garcia-Fabiani MB, Comba A, Kadiyala P, Haase S, Núñez FJ, Altshuler D, Lowenstein PR, Castro MG. Isolation and characterization of immune cells from the tumor microenvironment of genetically engineered pediatric high-grade glioma models using the sleeping beauty transposon system. Methods in Enzymology. 632: 369-388. PMID 32000905 DOI: 10.1016/Bs.Mie.2019.05.023  0.608
2020 Alghamri MS, Kamran N, Kadiyala P, Lowenstein PR, Castro MG. Functional assay to assess T-cell inhibitory properties of myeloid derived suppressor cells (MDSCs) isolated from the tumor microenvironment of murine glioma models. Methods in Enzymology. 632: 215-228. PMID 32000897 DOI: 10.1016/Bs.Mie.2019.05.047  0.606
2020 Gargini R, Segura-Collar B, Herránz B, García-Escudero V, Romero-Bravo A, Núñez FJ, García-Pérez D, Gutiérrez-Guamán J, Ayuso-Sacido A, Seoane J, Pérez-Núñez A, Sepúlveda-Sánchez JM, Hernández-Laín A, Castro MG, García-Escudero R, et al. The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas. Science Translational Medicine. 12. PMID 31969485 DOI: 10.1126/Scitranslmed.Aax1501  0.405
2020 Altshuler DB, Kadiyala P, Nuñez FJ, Nuñez FM, Carney S, Alghamri MS, Garcia-Fabiani MB, Asad AS, Nicola Candia AJ, Candolfi M, Lahann J, Moon JJ, Schwendeman A, Lowenstein PR, Castro MG. Prospects of biological and synthetic pharmacotherapies for glioblastoma. Expert Opinion On Biological Therapy. 1-13. PMID 31959027 DOI: 10.1080/14712598.2020.1713085  0.512
2020 Comba A, Dunn PJ, Argento AE, Kadiyala P, Ventosa M, Patel P, Zamler DB, Nunez FJ, Zhao L, Castro MG, Lowenstein PR. FYN tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates anti-glioma immune responses. Neuro-Oncology. PMID 31950181 DOI: 10.1093/neuonc/noaa006  0.492
2020 Alghamri MS, Núñez FJ, Kamran N, Carney S, Altshuler D, Lowenstein PR, Castro MG. Functional characterization of tumor antigen-specific T-cells isolated from the tumor microenvironment of sleeping beauty induced murine glioma models. Methods in Enzymology. 631: 91-106. PMID 31948569 DOI: 10.1016/Bs.Mie.2019.05.032  0.608
2020 Lowenstein P, Orringer D, Umemura Y, Sagher O, Heth J, Hervey-Jumper S, Mammoser A, Leung D, Lawrence T, Kim M, Wahl D, McKeever P, Camelo-Piragua S, Lieberman A, Venneti S, ... ... Castro MG, et al. Abstract CT105: First in human phase I trial of adenoviral vectors expressing Flt3L and HSV1-TK to treat newly diagnosed high-grade glioma by reprogramming the brain immune system Tumor Biology. DOI: 10.1158/1538-7445.Am2020-Ct105  0.542
2020 Comba A, Dunn P, Argento AE, Kadiyala P, Motsch S, Zamler D, Kahana A, Kish PE, Castro MG, Lowenstein PR. Abstract 3950: Spatiotemporal analysis of gliomas: Dynamics of mesenchymal multicellular structures as novel target for tumor treatment Tumor Biology. DOI: 10.1158/1538-7445.Am2020-3950  0.525
2020 Carney S, Zhu B, Kadiyala P, Garcia-Fabiani M, Gorla P, Nunez F, Lowenstein PR, Castro MG. Abstract 1266: Mutant IDH1 alters epigenetic regulation to promote stemness in low grade glioma: Deciphering signaling pathways altered by mIDH1 inhibition Cancer Research. 80: 1266-1266. DOI: 10.1158/1538-7445.Am2020-1266  0.543
2019 Scheetz L, Park KS, Li Q, Lowenstein PR, Castro MG, Schwendeman A, Moon JJ. Engineering patient-specific cancer immunotherapies. Nature Biomedical Engineering. PMID 31406259 DOI: 10.1038/S41551-019-0436-X  0.5
2019 Oliver CR, Altemus MA, Westerhof TM, Cheriyan H, Cheng X, Dziubinski M, Wu Z, Yates J, Morikawa A, Heth J, Castro MG, Leung BM, Takayama S, Merajver SD. A platform for artificial intelligence based identification of the extravasation potential of cancer cells into the brain metastatic niche. Lab On a Chip. PMID 30810557 DOI: 10.1039/C8Lc01387J  0.394
2019 Núñez FJ, Mendez FM, Kadiyala P, Alghamri MS, Savelieff MG, Garcia-Fabiani MB, Haase S, Koschmann C, Calinescu AA, Kamran N, Saxena M, Patel R, Carney S, Guo MZ, Edwards M, ... ... Castro MG, et al. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Science Translational Medicine. 11. PMID 30760578 DOI: 10.1126/Scitranslmed.Aaq1427  0.55
2019 Kadiyala P, Li D, Nunez FM, Altshuler D, Doherty R, Kuai R, Yu M, Kamran N, Edwards M, Moon JJ, Lowenstein PR, Castro MG, Schwendeman A. High Density Lipoprotein-Mimicking Nanodiscs for Chemo-Immunotherapy against Glioblastoma Multiforme. Acs Nano. PMID 30721028 DOI: 10.1021/Acsnano.8B06842  0.588
2019 Núñez FJ, Mendez FM, Garcia-Fabiani MB, Pardo J, Edwards M, Lowenstein PR, Castro MG. Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures. Journal of Visualized Experiments : Jove. PMID 30688315 DOI: 10.3791/58931  0.56
2019 Lowenstein PR, Orringer DA, Sagher O, Heth J, Hervey-Jumper SL, Mammoser AG, Junck L, Leung D, Umemura Y, Lawrence TS, Kim MM, Wahl DR, McKeever P, Camelo-Piragua SI, Lieberman A, ... ... Castro M, et al. First-in-human phase I trial of the combination of two adenoviral vectors expressing HSV1-TK and FLT3L for the treatment of newly diagnosed resectable malignant glioma: Initial results from the therapeutic reprogramming of the brain immune system. Journal of Clinical Oncology. 37: 2019-2019. DOI: 10.1200/Jco.2019.37.15_Suppl.2019  0.622
2019 Whalen MJ, Garcia-Fabiani MB, Núñez FJ, Lowenstein PR, Castro MG. Abstract 869: Molecular characterization of a pediatric high-grade glioma (pHGG) mouse model harboring the H3.3 G34R mutation Cancer Research. 79: 869-869. DOI: 10.1158/1538-7445.Sabcs18-869  0.583
2019 Carney S, Nuñez F, Lowenstein PR, Castro MG. Abstract 3414: Identifying dysregulated lncRNAs and miRNAs in low grade glioma: Uncovering signaling pathways and novel therapeutic targets Cancer Research. 79: 3414-3414. DOI: 10.1158/1538-7445.Am2019-3414  0.491
2019 Orringer DA, Sagher O, Heth J, Hervey-Jumper SL, Mammoser A, Junck L, Leung D, Umemura Y, Lawrence T, Kim M, Wahl D, McKeever P, Camelo-Piragua S, Lieberman A, Venneti S, ... ... Castro MG, et al. First in Human Phase I Trial of Dual Vector (HSV1-TK, Flt3L) Immunotherapy For The Treatment of Newly Diagnosed High-Grade Glioma: Initial Results Neurosurgery. 66. DOI: 10.1093/Neuros/Nyz310_152  0.633
2019 Nunez F, Garcia-Fabiani M, Kadiyala P, Hong H, Comba A, Lyssiotis C, Cheng S, Lowenstein P, Castro M. RDNA-03. AUTOPHAGY AS A NOVEL THERAPEUTIC TARGET IN MUTANT IDH1 GLIOMAS Neuro-Oncology. 21: vi207-vi207. DOI: 10.1093/Neuonc/Noz175.863  0.575
2019 B Garcia-Fabiani M, Kadiyala P, Haase S, Alghamri M, Comba A, Nunez F, Whalen M, Lowenstein P, Castro M. PDTM-20. THE HISTONE MUTATION H3.3-G34R ENCOUNTERED IN PEDIATRIC HIGH GRADE GLIOMA MODIFIES THE TUMOR IMMUNE MICROENVIRONMENT RENDERING IT MORE PERMISSIVE FOR IMMUNE MEDIATED THERAPIES Neuro-Oncology. 21: vi191-vi191. DOI: 10.1093/Neuonc/Noz175.796  0.576
2019 Kadiyala P, Nunez F, Garcia-Fabiani M, Nunez F, Li D, Schwendeman A, Lowenstein P, Castro M. IMMU-03. SUPPRESSION OF ONCOMETABOLITE 2-HYDROXYGLUTRATE PRODUCED BY MUTANT IDH1 GLIOMA WITH AGI-5198 ENHANCES THE EFFICACY OF RADIOTHERAPY AND IMMUNE CHECKPOINT BLOCKADE ELICITING IMMUNOLOGICAL MEMORY Neuro-Oncology. 21: vi119-vi119. DOI: 10.1093/Neuonc/Noz175.497  0.606
2019 Ventosa M, Kadiyala P, Carney S, Castro M, Lowenstein P. GENE-32. SYNTHETIC LETHAL INTERACTIONS WITH IDH1R132H IN GLIOMA STEM-LIKE CELLS Neuro-Oncology. 21: vi104-vi104. DOI: 10.1093/Neuonc/Noz175.434  0.578
2019 Mullan B, Qin T, Siada R, Ravindran R, Garcia T, Muruganand A, Harris M, Danussi C, Brosnan-Cashman J, Pratt D, Zhao X, Rehemtulla A, Sartor M, Venneti S, Meeker A, ... ... Castro M, et al. GENE-17. ATRX LOSS IN GLIOMA RESULTS IN EPIGENETIC DYSREGULATION OF THE G2/M CHECKPOINT AND SENSITIVITY TO ATM INHIBITION Neuro-Oncology. 21: vi101-vi101. DOI: 10.1093/Neuonc/Noz175.419  0.599
2019 Harris M, Yadav V, Stallard S, Woo R, Siddaway R, Qin T, Mullan B, Miklja Z, Siada R, Ravindran R, Cao X, Pasternak A, Castro M, Lowenstein P, Mody R, et al. EXTH-47. THERAPEUTIC REVERSAL OF PRENATAL PONTINE ID1 SIGNALING IN DIPG Neuro-Oncology. 21: vi92-vi92. DOI: 10.1093/Neuonc/Noz175.379  0.596
2019 Comba A, J Dunn P, E Argento A, Kadiyala P, Ventosa M, Patel P, Zamler D, Nunez F, Zhao L, Castro M, Lowenstein P. TMIC-62. FYN, AN EFFECTOR OF ONCOGENIC RECEPTOR TYROSINE KINASES SIGNALING IN GLIOBLASTOMA, INHIBITS ANTI-GLIOMA IMMUNE RESPONSES: IMPLICATIONS FOR IMMUNOTHERAPY Neuro-Oncology. 21: vi261-vi261. DOI: 10.1093/Neuonc/Noz175.1096  0.599
2019 Comba A, J Dunn P, E Argento A, Kadiyala P, Motsch S, Kahana A, E Kish P, Castro M, Lowenstein P. TMIC-58. THE CELLULAR AND MOLECULAR BASIS FOR MESENCHYMAL TRANSFORMATION IN GLIOMAS Neuro-Oncology. 21: vi260-vi260. DOI: 10.1093/Neuonc/Noz175.1092  0.607
2019 Alghamri M, Castro M, Lowenstein P, Kamran N, Kadiyala P, Avvari R, Zhang L. TMIC-35. IDH1 MUTATION IN GLIOMA REPROGRAMS EARLY MYELOID DIFFERENTIATION IN THE BONE MARROW (BM) TO PRODUCE NON-IMUNESUPPRESSIVE NEUTROPHILS Neuro-Oncology. 21: vi255-vi255. DOI: 10.1093/Neuonc/Noz175.1069  0.582
2019 Nabiul Hasan M, Guan X, Ahuja A, Castro M, Kohanbash G, Sun D. TMIC-19. H+ EXTRUSION PROTEIN NA/H EXCHANGER IN METABOLIC POLARIZATION OF GLIOMA-ASSOCIATED MICROGLIA/MACROPHAGES AND TUMOR IMMUNITY Neuro-Oncology. 21: vi251-vi251. DOI: 10.1093/Neuonc/Noz175.1053  0.412
2019 Lowenstein P, A Orringer D, Sagher O, Heth J, Hervey-Jumper S, Gerald Mammoser A, Junck L, Leung D, Umemura Y, Steven Lawrence T, Miran Kim M, Richard Wahl D, McKeever P, Ines Camelo-Piragua S, Lieberman A, ... ... Castro M, et al. ATIM-44. A PHASE I FIRST-IN-HUMAN TRIAL OF TWO ADENOVIRAL VECTORS EXPRESSING HSV1-TK AND FLT3L FOR TREATING NEWLY DIAGNOSED RESECTABLE MALIGNANT GLIOMA: THERAPEUTIC REPROGRAMMING OF THE BRAIN IMMUNE SYSTEM Neuro-Oncology. 21: vi11-vi11. DOI: 10.1093/Neuonc/Noz175.042  0.605
2019 Mendez F, Nunez F, Kadiyala P, Ravindran R, Nunez F, Pawar S, Williams J, Zorrilla-Veloz R, Swarnam U, Alcantara M, Parker E, Edwards M, Lowenstein P, Castro M. TMOD-08. ELUCIDATING EPIGENETIC MECHANISMS IN DIFFUSE INTRINSIC PONTINE GLIOMA HARBORING ACVR1 G328V AND H3.1 K27M Neuro-Oncology. 21: ii122-ii123. DOI: 10.1093/Neuonc/Noz036.246  0.448
2019 Fabiani MG, Haase S, Kadiyala P, Alghamri M, Comba A, Nuñez F, Whalen M, Lowenstein P, Castro M. TMOD-02. CHARACTERIZATION OF THE TUMOR IMMUNE MICROENVIRONMENT IN A PEDIATRIC HIGH GRADE GLIOMA MOUSE MODEL HARBORING THE H3.3-G34R MUTATION Neuro-Oncology. 21: ii121-ii121. DOI: 10.1093/Neuonc/Noz036.241  0.553
2019 Altshuler D, Yadav V, Rosales MV, Castro M, Lowenstein P. Lgg-17. Decreased Function Of Isoprenylcysteine Carboxylmethyltransferase Results In Increased Sensitivity To Chemoradiation In Oligodendroglioma Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz036.160  0.426
2019 Mullan B, Qin T, Siada R, Danussi C, Brosnan-Cashman J, Pratt D, Garcia T, Yadav VN, Zhao X, Morgan M, Venneti S, Meeker A, Huse J, Rehemtulla A, Lowenstein P, ... Castro M, et al. HGG-08. ATRX LOSS IN PEDIATRIC GBM RESULTS IN EPIGENETIC DYSREGULATION OF G2/M CHECKPOINT MAINTENANCE AND SENSITIVITY TO ATM INHIBITION Neuro-Oncology. 21: ii88-ii88. DOI: 10.1093/Neuonc/Noz036.102  0.447
2019 Comba A, Dunn P, Argento AE, Kadiyala P, Motsch S, Kish P, Kahana A, Zamler D, Muraszko K, Castro MG, Lowenstein PR. 3131 ONCOSTREAMS: NOVEL DYNAMICS PATHOLOGICAL MULTICELLULAR STRUCTURES INVOLVED IN GLIOBLATOMA GROWTH AND INVASION Journal of Clinical and Translational Science. 3: 111-111. DOI: 10.1017/cts.2019.253  0.528
2019 Zhou W, Yao Y, Pratt D, Zhao S, Dresser J, Davis M, Castro M, Lowenstein P, Chandrasekaran S, Lawrence T, Lyssiotis C, Wahl D. De Novo Purine Synthesis Is a Targetable Vulnerability That Confers Radiation Resistance and Inferior Patient Survival in IDH-Wild Type Diffuse Glioma International Journal of Radiation Oncology*Biology*Physics. 105: S76-S77. DOI: 10.1016/j.ijrobp.2019.06.536  0.394
2018 Guan X, Hasan MN, Begum G, Kohanbash G, Carney KE, Pigott VM, Persson AI, Castro MG, Jia W, Sun D. Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy. Cell Death & Disease. 9: 1010. PMID 30262908 DOI: 10.1038/S41419-018-1062-3  0.437
2018 Haase S, Garcia-Fabiani MB, Carney S, Altshuler D, Núñez FJ, Méndez FM, Núñez F, Lowenstein PR, Castro MG. Mutant ATRX: uncovering a new therapeutic target for glioma. Expert Opinion On Therapeutic Targets. PMID 29889582 DOI: 10.1080/14728222.2018.1487953  0.504
2018 Yadav VN, Altshuler D, Kadiyala P, Zamler D, Comba A, Appelman H, Dunn P, Koschmann C, Castro MG, Löwenstein PR. Molecular Ablation of Tumor Blood Vessels Inhibits Therapeutic Effects of Radiation and Bevacizumab. Neuro-Oncology. PMID 29660022 DOI: 10.1093/Neuonc/Noy055  0.529
2018 Mendez FM, Núñez FJ, Zorrilla-Veloz RI, Lowenstein PR, Castro MG. Native Chromatin Immunoprecipitation Using Murine Brain Tumor Neurospheres. Journal of Visualized Experiments : Jove. PMID 29443090 DOI: 10.3791/57016  0.549
2018 Kamran N, Alghamri MS, Nunez FJ, Shah D, Asad AS, Candolfi M, Altshuler D, Lowenstein PR, Castro MG. Current state and future prospects of immunotherapy for glioma. Immunotherapy. 10: 317-339. PMID 29421984 DOI: 10.2217/Imt-2017-0122  0.574
2018 Kamran N, Li Y, Sierra M, Alghamri MS, Kadiyala P, Appelman HD, Edwards M, Lowenstein PR, Castro MG. Melanoma induced immunosuppression is mediated by hematopoietic dysregulation. Oncoimmunology. 7: e1408750. PMID 29399415 DOI: 10.1080/2162402X.2017.1408750  0.571
2018 Ravindran R, Mendez FM, Nunez FJ, Koschmann C, Dzaman M, Pawar S, Lowenstein PR, Castro MG. Abstract 5101: Characterization of a mouse model using the Sleeping Beauty transposon method to study diffuse intrinsic pontine glioma (DIPG) Cancer Research. 78: 5101-5101. DOI: 10.1158/1538-7445.Am2018-5101  0.57
2018 Oliver CR, Altemus M, Westerhof T, Morikawa A, Cheng X, Heth J, Takayama S, Castro M, Merajver S. Abstract 3103: Analysis of breast cancer lines and PDXs using a blood brain niche (µm-BBN) microfluidic device and algorithms to aid diagnosis of brain metastatic potential Cancer Research. 78: 3103-3103. DOI: 10.1158/1538-7445.Am2018-3103  0.35
2018 Haase S, Belén Garcia-Fabiani M, Nunez F, Kadiyala P, Nunez F, Lowenstein P, Castro M. PDTM-20. ELUCIDATING MOLECULAR PATHOGENIC MECHANISMS OF THE HISTONE H3.3 G34R MUTATION IN PEDIATRIC HIGH-GRADE GLIOMAS (HGGs) Neuro-Oncology. 20: vi208-vi208. DOI: 10.1093/Neuonc/Noy148.862  0.466
2018 Alghamri M, Kamran N, Nunez F, Kadiyala P, Zhang L, Avvari R, Lowenstein P, Castro M. IMMU-63. IDH1 MUTATION REGULATE MYELOID CELLS PLASTICITY MEDIATING ANTI-GLIOMA IMMUNOTHERAPY Neuro-Oncology. 20: vi135-vi136. DOI: 10.1093/Neuonc/Noy148.566  0.514
2018 Kadiyala P, Nunez F, Li D, Schwendeman A, Lowenstein P, Castro M. IMMU-61. INHIBITION OF MUTANT IDH1 WITH AGI-5198 ENHANCES THE EFFICACY OF RADIOTHERAPY ELICITING IMMUNOLOGICAL MEMORY AND IMPROVING OVERALL SURVIVAL Neuro-Oncology. 20: vi135-vi135. DOI: 10.1093/Neuonc/Noy148.564  0.468
2018 Nunez F, Mendez F, Kadiyala P, Alghamri M, Carney S, Ljungman M, Qin T, Sartor M, Venneti S, Lyssiotis C, Costello J, Herting C, Hambardzumyan D, Figueroa M, Lowenstein P, ... Castro M, et al. GENE-35. IDH1-R132H INDUCES AN EPIGENETIC REPROGRAMMING IN GLIOMA IMPACTING MEDIAN SURVIVAL, DNA-DAMAGE RESPONSE AND RADIO-SENSITIVITY Neuro-Oncology. 20: vi111-vi111. DOI: 10.1093/Neuonc/Noy148.461  0.494
2018 Mendez F, Nunez F, Koschmann C, Ravindran R, Dzaman M, Lowenstein P, Castro M. GENE-34. MOUSE MODEL OF DIFFUSE INTRINSIC PONTINE GLIOMA HARBORING Acvr1 G328V Neuro-Oncology. 20: vi110-vi111. DOI: 10.1093/Neuonc/Noy148.460  0.496
2018 Stallard S, Siddaway R, Miklja Z, Mullan B, Garcia T, Zamler D, Kasaian K, Cao X, Anderson B, Hervey-Jumper S, Castro MG, Lowenstein PR, Mody R, Chinnaiyan A, Venneti S, et al. DIPG-38. ID1 EXPRESSION CORRELATES WITH H3F3A K27M MUTATION AND EXTRA-PONTINE INVASION IN DIPG Neuro-Oncology. 20: i56-i56. DOI: 10.1093/Neuonc/Noy059.131  0.463
2017 Koschmann C, Farooqui Z, Kasaian K, Cao X, Zamler D, Stallard S, Venneti S, Hervey-Jumper S, Garton H, Muraszko K, Franchi L, Robertson PL, Leonard M, Opipari V, Castro MG, et al. Multi-focal sequencing of a diffuse intrinsic pontine glioma establishes PTEN loss as an early event. Npj Precision Oncology. 1: 32. PMID 29872713 DOI: 10.1038/s41698-017-0033-y  0.421
2017 Lowenstein PR, Castro MG. Evolutionary basis of a new approach for the treatment of malignant brain tumors: From mice to humans. Clinical Immunology (Orlando, Fla.). PMID 28720549 DOI: 10.1016/J.Clim.2017.07.006  0.628
2017 Chandran M, Candolfi M, Shah D, Mineharu Y, Yadav V, Koschmann C, Asad AS, Lowenstein PR, Castro MG. Single vs. combination immunotherapeutic strategies for glioma. Expert Opinion On Biological Therapy. PMID 28286975 DOI: 10.1080/14712598.2017.1305353  0.602
2017 Kamran N, Kadiyala P, Saxena M, Candolfi M, Li Y, Moreno-Ayala MA, Raja N, Shah D, Lowenstein PR, Castro MG. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 25: 232-248. PMID 28129117 DOI: 10.1016/J.Ymthe.2016.10.003  0.621
2017 Koschmann C, Nunez FJ, Mendez F, Brosnan-Cashman JA, Meeker AK, Lowenstein PR, Castro MG. Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer. Cancer Research. PMID 28062403 DOI: 10.1158/0008-5472.Can-16-2301  0.512
2017 Ashley SL, Pretto CD, Stier MT, Kadiyala P, Castro-Jorge L, Hsu TH, Doherty R, Carnahan KE, Castro MG, Lowenstein PR, Spindler KR. Matrix Metalloproteinase Activity in Infections by an Encephalitic Virus, Mouse Adenovirus Type 1. Journal of Virology. PMID 28053109 DOI: 10.1128/Jvi.01412-16  0.473
2017 Alghamri MS, Kamran N, Nunez FJ, Lowenstein PR, Castro MG. IMMU-58. IDH1 MUTATION REGULATES MYELOID CELLS MEDIATED IMMUNOSUPPRESSION IN GLIOMA Neuro-Oncology. 19: vi125-vi126. DOI: 10.1093/Neuonc/Nox168.516  0.512
2017 Shah D, Kadiyala P, Kamran N, Baker GJ, Doherty R, Zamler D, Nuñez G, Castro MG, Lowenstein PR. IMMU-26. TLR7 ACTIVATION IS ESSENTIAL FOR NK CELLS TO ELIMINATE GLIOMA TUMORS Neuro-Oncology. 19: vi118-vi118. DOI: 10.1093/Neuonc/Nox168.484  0.561
2017 Nunez FJ, Mendez FM, Kadiyala P, Savelieff M, Koschmann C, Carney S, Patel R, Manawar S, Kamran N, Saxena M, Ljungman M, Qin T, Maureen S, Dzaman M, Vennneti S, ... ... Castro MG, et al. GENE-58. EPIGENETIC REPROGRAMMING IN MUTANT IDH1 GLIOMA IMPACTS MEDIAN SURVIVAL, ENHANCES DNA DAMAGE RESPONSE AND CONFERS RADIO-RESISTANCE Neuro-Oncology. 19: vi105-vi105. DOI: 10.1093/Neuonc/Nox168.430  0.493
2017 Mendez FM, Nunez FJ, Koschmann C, Saxena M, Kamran N, Dzaman M, Pawar S, Lowenstein PR, Castro MG. GENE-17. GENERATION OF A MOUSE MODEL OF DIFFUSE INTRINSIC PONTINE GLIOMA HARBORING ACVR1 G328V AND H3.1 K27M MUTATIONS Neuro-Oncology. 19: vi96-vi96. DOI: 10.1093/Neuonc/Nox168.391  0.487
2017 Comba A, Kadiyala P, Argento AE, Patel P, Nunez FJ, Saxena M, Castro MG, Lowenstein PR. CSIG-39. Fyn, AN ONCOGENE THAT REDUCES GLIOBLASTOMA SURVIVAL YET SENSITIZES TO CHEMO-RADIOTHERAPY Neuro-Oncology. 19: vi58-vi58. DOI: 10.1093/Neuonc/Nox168.233  0.466
2017 Comba A, Zamler D, Argento AE, Koschmann C, Nunez FJ, Edwards M, Kadiyala P, Kamran N, Yadav VN, Motsch S, Castro MG, Lowenstein PR. CSIG-11. ONCOSTREAMS: NOVEL STRUCTURES THAT SPECIFY GLIOMAS’ SELF-ORGANIZATION, ARE ANATOMICALLY DISCRETE, FUNCTIONALLY UNIQUE, AND MOLECULARLY DISTINCT Neuro-Oncology. 19: vi52-vi52. DOI: 10.1093/Neuonc/Nox168.206  0.417
2017 Yadav VN, Kadiyala P, Zamler D, Gutierrez A, Koschmann C, Castro MG, Lowenstein PR. ANGI-11. DIRECT GLIOMA BLOOD VESSEL DISRUPTION IMPROVES IMMUNE THERAPY BUT WORSENS ANTI-VEGF THERAPY Neuro-Oncology. 19: vi23-vi24. DOI: 10.1093/Neuonc/Nox168.089  0.511
2016 Yadav VN, Zamler D, Baker GJ, Kadiyala P, Erdreich-Epstein A, DeCarvalho AC, Mikkelsen T, Castro MG, Lowenstein PR. CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study. Oncotarget. PMID 27863376 DOI: 10.18632/Oncotarget.13295  0.61
2016 Kamran N, Chandran M, Lowenstein PR, Castro MG. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy. Clinical Immunology (Orlando, Fla.). PMID 27777083 DOI: 10.1016/J.Clim.2016.10.008  0.618
2016 Koschmann C, Zamler D, MacKay A, Robinson D, Wu YM, Doherty R, Marini B, Tran D, Garton H, Muraszko K, Robertson P, Leonard M, Zhao L, Bixby D, Peterson L, ... ... Castro MG, et al. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma. Oncotarget. PMID 27582545 DOI: 10.18632/Oncotarget.11602  0.534
2016 Wilson TJ, Zamler DB, Doherty R, Castro MG, Lowenstein PR. Reversibility of glioma stem cells' phenotypes explains their complex in vitro and in vivo behavior. Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells. Oncotarget. PMID 27564115 DOI: 10.18632/Oncotarget.11589  0.556
2016 Calinescu AA, Yadav VN, Carballo E, Kadiyala P, Tran D, Zamler D, Doherty R, Srikanth M, Lowenstein PR, Castro MG. Survival and proliferation of neural progenitor derived glioblastomas under hypoxic stress is controlled by a CXCL12/CXCR4 autocrine positive feedback mechanism. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27542769 DOI: 10.1158/1078-0432.Ccr-15-2888  0.536
2016 Lowenstein PR, Castro MG. Multiple expressed endogenous glioma epitopes as novel vaccines for gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27521444 DOI: 10.1158/1078-0432.Ccr-16-1477  0.581
2016 Baker GJ, Chockley P, Zamler D, Castro MG, Lowenstein PR. Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells. Oncoimmunology. 5: e1163461. PMID 27471637 DOI: 10.1080/2162402X.2016.1163461  0.593
2016 Kamran N, Calinescu A, Candolfi M, Chandran M, Mineharu Y, Assad AS, Koschmann C, Nunez F, Lowenstein P, Castro M. Recent advances and future of immunotherapy for glioblastoma. Expert Opinion On Biological Therapy. PMID 27411023 DOI: 10.1080/14712598.2016.1212012  0.482
2016 Koschmann C, Lowenstein PR, Castro MG. ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability. Molecular & Cellular Oncology. 3: e1167158. PMID 27314101 DOI: 10.1080/23723556.2016.1167158  0.473
2016 Lowenstein PR, Castro MG. The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors. Advances in Pharmacology (San Diego, Calif.). 76: 147-73. PMID 27288077 DOI: 10.1016/Bs.Apha.2016.03.002  0.627
2016 VanderVeen NT, Raja NS, Yi E, Appelman H, Ng P, Palmer D, Zamler D, Dzaman M, Lowenstein P, Castro M. Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model. Human Gene Therapy Methods. PMID 27056322 DOI: 10.1089/Hgtb.2015.168  0.615
2016 Koschmann C, Calinescu AA, Nunez FJ, Mackay A, Fazal-Salom J, Thomas D, Mendez F, Kamran N, Dzaman M, Mulpuri L, Krasinkiewicz J, Doherty R, Lemons R, Brosnan-Cashman JA, Li Y, ... ... Castro MG, et al. ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. Science Translational Medicine. 8: 328ra28. PMID 26936505 DOI: 10.1126/Scitranslmed.Aac8228  0.524
2016 Kamran N, Candolfi M, Baker GJ, Ayala MM, Dzaman M, Lowenstein PR, Castro MG. Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms. Methods in Molecular Biology (Clifton, N.J.). 1382: 467-82. PMID 26611605 DOI: 10.1007/978-1-4939-3271-9_31  0.587
2016 Altemus M, Leung B, Morikawa A, Dziubinski M, Castro M, Merajver S. Abstract 1700: Novel microfluidic blood-brain niche to study breast cancer metastasis to the brain Cancer Research. 76: 1700-1700. DOI: 10.1158/1538-7445.Am2016-1700  0.353
2016 Mendez FM, Nunez FJ, Koschmann C, Calinescu A, Saxena M, Kamran N, Pawar S, Dzaman M, Lowenstein PR, Castro MG. TMOD-11. USING THE SLEEPING BEAUTY TRANSPOSASE SYSTEM TO GENERATE MOUSE MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA HARBORING ACVR1 AND H3K27M MUTATIONS Neuro-Oncology. 18: vi209-vi209. DOI: 10.1093/Neuonc/Now212.881  0.45
2016 Koschmann C, Marini B, Colon LB, Wu Y, Kumar C, Lonigro R, Vats P, Cao X, Zamler D, Camelo-Piragua S, Vennneti S, Keever PM, McFadden K, Lieberman A, Shao L, ... ... Castro MG, et al. PDCT-03. CLINICALLY INTEGRATED SEQUENCING IN THE MANAGEMENT OF CHILDREN WITH HIGH-RISK BRAIN TUMORS Neuro-Oncology. 18: vi145-vi146. DOI: 10.1093/Neuonc/Now212.607  0.505
2016 Lowenstein P, Motsch S, Yadav VN, Zamler D, Comba A, Koschmann C, Nunez FJ, Calinescu A, Kamran N, Dzaman M, Castro MG. GENT-53. SELF-ORGANIZATION OF GLIOMAS: GENETIC RODENT MODELS, GENOMIC NETWORKS, AND MATHEMATICAL MODELING Neuro-Oncology. 18: vi85-vi85. DOI: 10.1093/Neuonc/Now212.357  0.44
2016 Koschmann C, Zamler D, MacKay A, Robinson D, Wu Y, Doherty R, Marini B, Tran D, Garton H, Muraszko K, Robertson P, Leonard M, Zhao L, Bixby D, Peterson L, ... ... Castro MG, et al. GENT-10. CHARACTERIZING AND TARGETING PDGFRA ALTERATIONS IN PEDIATRIC HIGH-GRADE GLIOMA Neuro-Oncology. 18: vi75-vi75. DOI: 10.1093/Neuonc/Now212.316  0.499
2016 Nunez FJ, Mendez FM, Koschmann C, Calinescu A, Saxena M, Kadiyala P, Savelieff M, Patel R, Manawar S, Venneti S, Dzaman M, Lowenstein PR, Castro MG. GENT-06. IN VIVO EXPRESSION OF MUTATED IDH1 (R132H) GENE IN A MOUSE MODEL OF YOUNG ADULT GLIOBLASTOMA HAS IMPACT IN MEDIAN SURVIVAL, DNA-REPAIR PATHWAYS, AUTOPHAGY AND OLIGODENDROCYTE DIFFERENTIATION Neuro-Oncology. 18: vi74-vi74. DOI: 10.1093/Neuonc/Now212.312  0.503
2016 Wilson T, Zamler D, Doherty R, Mikkelsen T, deCarvalho A, Castro M, Lowenstein P. CBIO-10. REVERSIBILITY OF GLIOMA STEM CELLS’ SPHERE FORMATION EXPLAINS THEIR IN VITRO BEHAVIOR AND IN VIVO TUMORIGENESIS POTENTIAL Neuro-Oncology. 18: vi37-vi37. DOI: 10.1093/Neuonc/Now212.148  0.462
2016 Yadav VN, Zamler D, Motsch S, Castro MG, Lowenstein PR. ANGI-10. GENETIC DOWN REGULATION OF CXCR4 IN GLIOMA CELLS REDUCES INVASION, REDUCES TUMOR PROGRESSION, AND INCREASES SENSITIVITY TO RADIATION Neuro-Oncology. 18: vi17-vi17. DOI: 10.1093/Neuonc/Now212.065  0.55
2015 Baker GJ, Castro MG, Lowenstein PR. Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells. Journal of Visualized Experiments : Jove. PMID 26650233 DOI: 10.3791/53676  0.608
2015 Calinescu AA, Kamran N, Baker G, Mineharu Y, Lowenstein PR, Castro MG. Overview of current immunotherapeutic strategies for glioma. Immunotherapy. 7: 1073-104. PMID 26598957 DOI: 10.2217/Imt.15.75  0.545
2015 Calinescu AA, Núñez FJ, Koschmann C, Kolb BL, Lowenstein PR, Castro MG. Transposon mediated integration of plasmid DNA into the subventricular zone of neonatal mice to generate novel models of glioblastoma. Journal of Visualized Experiments : Jove. PMID 25741859 DOI: 10.3791/52443  0.567
2015 Lowenstein PR, Castro MG. Glioma trials and viral tribulations: can anything be concluded from non-controlled trials? Journal of Neurology, Neurosurgery, and Psychiatry. 86: 125. PMID 25280917 DOI: 10.1136/Jnnp-2014-308406  0.466
2015 Kamran N, Li Y, Moreno-Ayala M, Assi H, Candolfi M, Dzaman M, Lowenstein P, Castro M. Abstract 457: Depletion of glioma infiltrating myeloid derived suppressor cells promotes anti-tumor T cell responses Cancer Research. 75: 457-457. DOI: 10.1158/1538-7445.Am2015-457  0.608
2015 Baker GJ, Chockley P, Zamler D, Yadav VN, Castro MG, Lowenstein PR. Abstract 452: Monocytic Gr-1+/CD11b+ myeloid cells are necessary for natural killer cells to eradicate glioma and are inhibited by tumor-derived galectin-1 Cancer Research. 75: 452-452. DOI: 10.1158/1538-7445.Am2015-452  0.577
2015 Yadav VN, Baker GJ, Narayanan S, Castro MG, Lowenstein PR. Abstract 4145: Brain-derived endothelial cells stimulate migration of different human, mouse, and rat glioma cell lines in vivo and in vitro Cancer Research. 75: 4145-4145. DOI: 10.1158/1538-7445.Am2015-4145  0.565
2015 VanderVeen NT, Raja N, Yi E, Curtin J, Chockley P, Assi H, Savakus J, Mikkelsen T, Rabkin S, Lowenstein PR, Castro MG. Abstract 3195: STAT3 inhibition using shRNA inhibits GBM proliferation, cell migration, anchorage-independent growth of mouse, rat, and human stem-like cells in vitro; and it induces long term survival and anti-GBM immunity in vivo Cancer Research. 75: 3195-3195. DOI: 10.1158/1538-7445.Am2015-3195  0.619
2015 Nunez FJ, Mendez FM, Koschmann C, Calinescu A, Lowenstein PR, Castro MG. Abstract 3033: Generation of a mouse model of young adult glioblatoma: In vivo expression of mutated IDH1-R132H gene using the sleeping beauty transposase system Cancer Research. 75: 3033-3033. DOI: 10.1158/1538-7445.Am2015-3033  0.554
2015 Koschmann C, Calinescu A, Thomas D, Nunez FJ, Dzaman M, Krasinkiewicz J, Lemons R, Kamran N, Mendez F, Roh S, Ferguson D, Lowenstein PR, Castro MG. Abstract 3009: ATRX validated as tumor suppressor in a novel mouse model of pediatric and young adult GBM Cancer Research. 75: 3009-3009. DOI: 10.1158/1538-7445.Am2015-3009  0.58
2015 Mendez F, Nunez F, Koschmann C, Calinescu A, Kamran N, Dzaman M, Lowenstein P, Castro M. TMOD-05MODELING ACVR1 AND HIST1H3B MUTATIONS IN DIFFUSE INTRINSIC PONTINE GLIOMAIN VIVOUSING THE SLEEPING BEAUTY SYSTEM Neuro-Oncology. 17: v227.1-v227. DOI: 10.1093/Neuonc/Nov237.05  0.524
2015 Calinescu A, Carballo E, Tran D, Zamler D, Doherty R, Lowenstein P, Castro M. TMOD-02BLOCKING CXCR4 INCREASES SURVIVAL IN A MOUSE MODEL OF NEURAL STEM CELLS-DERIVED GLIOBLASTOMA BY BLOCKING AN AUTOCRINE POSITIVE FEEDBACK LOOP REGULATING APOPTOSIS AND CELL CYCLE PROGRESSION VIA Rb1 AND cdk4/cdk6/CyclinD1 Neuro-Oncology. 17: v226.2-v226. DOI: 10.1093/Neuonc/Nov237.02  0.503
2015 Kamran N, Stallard S, Raja N, Ayala M, Calinescue A, Nunez F, Andjelkovic A, Lowenstein P, Castro M. TMIC-15MYELOID DERIVED SUPPRESSOR CELLS' TRAFFICKING INTO GBM IS REGULATED BY CXCR2 SIGNALING Neuro-Oncology. 17: v217.7-v217. DOI: 10.1093/Neuonc/Nov236.15  0.495
2015 Kamran N, Li Y, Ayala MM, Raja N, Nunez F, Assi H, Lowenstein P, Castro M. TMIC-14DEPLETION OF GLIOMA INFILTRATING MYELOID DERIVED SUPPRESSOR CELLS PROMOTES ANTI-TUMOR T CELL RESPONSES Neuro-Oncology. 17: v217.6-v217. DOI: 10.1093/Neuonc/Nov236.14  0.572
2015 Koschmann C, Calinescu A, Nunez F, Mckay A, Salom JF, Thomas D, Mulpuri L, Kamran N, Mendez F, Dzaman M, Krasinkiewicz J, Lemons R, Zhao L, Appelman H, Ferguson D, ... ... Castro MG, et al. PTPS-15ATRX LOSS PROMOTES TUMOR GROWTH AND IMPAIRS NON-HOMOLOGOUS END JOINING DNA REPAIR IN GLIOMA Neuro-Oncology. 17: v182.2-v182. DOI: 10.1093/Neuonc/Nov228.15  0.524
2015 Lowenstein P, Motsch S, Koschmann C, Nuñez-Aguilera F, Baker G, Calinescu A, Kamran N, Yadav VA, Zamler D, Dzaman M, Castro M. MPTH-18STREAMS, VORTICES, AND NEUROSPHERES: IN VIVO NON-RANDOM LARGE SCALE SELF-ORGANIZATION OF GLIOBLASTOMA MULTIFORME AND THE ROLE OF NOVEL HISTOPATHOLOGICAL STRUCTURES Neuro-Oncology. 17: v142.1-v142. DOI: 10.1093/Neuonc/Nov222.18  0.559
2015 Baker G, Chockley P, Zamler D, Castro M, Lowenstein P. IMPS-01Gr-1+/CD11b+MYELOID CELLS ARE REQUIRED FOR NATURAL KILLER CELL-MEDIATED ERADICATION OF GALECTIN-1-DEFICIENT GLIOMA Neuro-Oncology. 17: v113.1-v113. DOI: 10.1093/Neuonc/Nov217.01  0.598
2015 Yadav VN, Baker GJ, Orringer DA, Heth JA, Hervey-Jumper S, Sagher O, Castro MG, Lowenstein PR. ANGI-16IN VIVO AND IN VITRO STUDIES SHOW THAT BRAIN DERIVED ENDOTHELIAL CELLS STIMULATE MIGRATION OF HUMAN, MOUSE AND RAT GLIOMA CELLS Neuro-Oncology. 17: v44.3-v44. DOI: 10.1093/Neuonc/Nov207.16  0.555
2015 Nunez FJ, Mendez FM, Koschmann C, Calinescu A, Dzaman M, Lowenstein PR, Castro MG. HG-03 * A NOVEL MOUSE MODEL OF YOUNG ADULT GLIOBLASTOMA: IN VIVO EXPRESSION OF MUTATED IDH1 (R132H) GENE USING THE SLEEPING BEAUTY TRANSPOSASE SYSTEM Neuro-Oncology. 17: iii11-iii11. DOI: 10.1093/Neuonc/Nov061.40  0.573
2015 Koschmann C, Calinescu A, Thomas D, Nunez FJ, Dzaman M, Krasinkiewicz J, Kamran N, Lemons R, Mendez F, Li Y, Ferguson D, Gorbunova V, Roh S, Zhao L, Meeker A, ... ... Castro MG, et al. HG-02 * ATRX LOSS PROMOTES TUMOR GROWTH AND IMPAIRS GENETIC STABILITY IN GLIOBLASTOMA Neuro-Oncology. 17: iii10-iii11. DOI: 10.1093/Neuonc/Nov061.39  0.58
2014 Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 3: e955691. PMID 25941621 DOI: 10.4161/21624011.2014.955691  0.536
2014 Lowenstein PR, Baker GJ, Castro MG. Cracking the glioma-NK inhibitory code: toward successful innate immunotherapy. Oncoimmunology. 3: e965573. PMID 25941594 DOI: 10.4161/21624011.2014.965573  0.555
2014 Mineharu Y, Kamran N, Lowenstein PR, Castro MG. Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions. Molecular Cancer Therapeutics. 13: 3024-36. PMID 25256739 DOI: 10.1158/1535-7163.Mct-14-0400  0.567
2014 Baker GJ, Yadav VN, Motsch S, Koschmann C, Calinescu AA, Mineharu Y, Camelo-Piragua SI, Orringer D, Bannykh S, Nichols WS, deCarvalho AC, Mikkelsen T, Castro MG, Lowenstein PR. Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia (New York, N.Y.). 16: 543-61. PMID 25117977 DOI: 10.1016/J.Neo.2014.06.003  0.586
2014 VanderVeen N, Paran C, Appelhans A, Krasinkiewicz J, Lemons R, Appelman H, Doherty R, Palmer D, Ng P, Lowenstein PR, Castro MG. Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors. Molecular Therapy. Methods & Clinical Development. 1. PMID 25068145 DOI: 10.1038/Mtm.2013.10  0.589
2014 Baker GJ, Chockley P, Yadav VN, Doherty R, Ritt M, Sivaramakrishnan S, Castro MG, Lowenstein PR. Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. Cancer Research. 74: 5079-90. PMID 25038230 DOI: 10.1158/0008-5472.Can-14-1203  0.592
2014 Castro MG, Baker GJ, Lowenstein PR. Blocking immunosuppressive checkpoints for glioma therapy: the more the Merrier! Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5147-9. PMID 24879798 DOI: 10.1158/1078-0432.Ccr-14-0820  0.533
2014 Lowenstein PR, Castro MG. The value of EGFRvIII as the target for glioma vaccines. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 42-50. PMID 24857059 DOI: 10.14694/EdBook_AM.2014.34.42  0.554
2014 Assi H, Espinosa J, Suprise S, Sofroniew M, Doherty R, Zamler D, Lowenstein PR, Castro MG. Assessing the role of STAT3 in DC differentiation and autologous DC immunotherapy in mouse models of GBM. Plos One. 9: e96318. PMID 24806510 DOI: 10.1371/Journal.Pone.0096318  0.556
2014 Castro MG, Candolfi M, Wilson TJ, Calinescu A, Paran C, Kamran N, Koschmann C, Moreno-Ayala MA, Assi H, Lowenstein PR. Adenoviral vector-mediated gene therapy for gliomas: coming of age. Expert Opinion On Biological Therapy. 14: 1241-57. PMID 24773178 DOI: 10.1517/14712598.2014.915307  0.607
2014 Lynes J, Wibowo M, Koschmann C, Baker GJ, Saxena V, Muhammad AK, Bondale N, Klein J, Assi H, Lieberman AP, Castro MG, Lowenstein PR. Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 623-35. PMID 24752661 DOI: 10.1007/S13311-014-0269-Y  0.585
2014 Assi HH, Paran C, VanderVeen N, Savakus J, Doherty R, Petruzzella E, Hoeschele JD, Appelman H, Raptis L, Mikkelsen T, Lowenstein PR, Castro MG. Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy. The Journal of Pharmacology and Experimental Therapeutics. 349: 458-69. PMID 24696041 DOI: 10.1124/Jpet.114.214619  0.582
2014 Candolfi M, Yagiz K, Wibowo M, Ahlzadeh GE, Puntel M, Ghiasi H, Kamran N, Paran C, Lowenstein PR, Castro MG. Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1555-65. PMID 24501391 DOI: 10.1158/1078-0432.Ccr-13-2140  0.604
2014 Lowenstein PR, Yadav VN, Chockley P, Castro M. There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 246-7. PMID 24487564 DOI: 10.1038/Mt.2013.297  0.591
2014 Baker GJ, Yadav VN, Motsch S, Koschmann CJ, Calinescu A, Mineharu Y, Camelo-Piragua SI, Orringer D, Bannykh SI, Nichols WS, deCarvalho AC, Mikkelsen T, Castro M, Lowenstein PR. Therapeutic implications of perivascular invasion in the context of high-density brain microvascular networks: A study on recursive pattern formation in malignant glioma. Journal of Clinical Oncology. 32: 2057-2057. DOI: 10.1200/Jco.2014.32.15_Suppl.2057  0.552
2014 Koschmann C, Calinescu A, Dzaman M, Lemons R, Thomas D, Castro MG, Lowenstein PR. Abstract 995: Loss of ATRX decreases survival and improves response to DNA damaging agents in a novel mouse model of glioblastoma Cancer Research. 74: 995-995. DOI: 10.1158/1538-7445.Am2014-995  0.588
2014 Assi H, Paran C, Savakus J, Hoeschle J, Raptis L, Lowenstein PR, Castro MG. Abstract 3804: CPA-7, an inhibitor of STAT3, is a potent tumoricidal agent in peripheral tumor models and is impermeable to the CNS Cancer Research. 74: 3804-3804. DOI: 10.1158/1538-7445.Am2014-3804  0.581
2014 Baker GJ, Yadav VN, Chockley P, Doherty R, Ritt M, Sivaramakrishnan S, Castro MG, Lowenstein PR. Abstract 3651: Natural killer cells eradicate galectin-1 deficient glioma in the absence of adaptive immunity Cancer Research. 74: 3651-3651. DOI: 10.1158/1538-7445.Am2014-3651  0.603
2014 Calinescu A, Assi H, Kolb B, Koschmann C, Lowenstein PR, Ohlfest J, Castro MG. Abstract 187: Absence of S100A9 confers survival advantage in an aggressive de novo mouse model of glioblastoma multiforme Cancer Research. 74: 187-187. DOI: 10.1158/1538-7445.Am2014-187  0.622
2014 Kamran N, Assi H, Candolfi M, Moreno M, Li Y, Lowenstein PR, Castro MG. Abstract 1085: Glioma-infiltrating myeloid derived suppressor cells inhibit anti-tumor T cell responses Cancer Research. 74: 1085-1085. DOI: 10.1158/1538-7445.Am2014-1085  0.59
2014 Koschmann C, Calinescu A, Thomas D, Kamran N, Nunez-Aguilera F, Dzaman M, Lemons R, Li Y, Roh H, Lowenstein P, Castro M. PM-07 * LOSS OF ATRX DECREASES SURVIVAL AND IMPROVES RESPONSE TO DNA DAMAGING AGENTS IN A NOVEL MOUSE MODEL OF GLIOBLASTOMA Neuro-Oncology. 16: v170-v170. DOI: 10.1093/Neuonc/Nou268.7  0.573
2014 Kamran N, Ayala M, Li Y, Assi H, Candolfi M, Dzaman M, Lowenstein P, Castro M. ME-10 * TUMOR MICROENVIRONMENT INFILTRATING MYELOID DERIVED SUPPRESSOR CELLS INHIBIT ANTI-TUMOR T CELL RESPONSES Neuro-Oncology. 16: v121-v122. DOI: 10.1093/Neuonc/Nou261.9  0.579
2014 Baker G, Chockley P, Yadav V, Doherty R, Ritt M, Sivaramakrishnan S, Castro M, Lowenstein P. IB-01 * GLIOMA-DERIVED GALECTIN-1 IS A POTENT SUPPRESSOR OF NK IMMUNOSURVEILLANCE Neuro-Oncology. 16: v107-v107. DOI: 10.1093/Neuonc/Nou257.1  0.605
2014 Baker G, Yadav V, Motsch S, Koschmann C, Calinescu A, Mineharu Y, Camelo-Piragua S, Orringer D, Bannykh S, Nichols W, deCarvalho A, Mikkelsen T, Castro M, Lowenstein P. AI-04 * MECHANISMS OF GLIOMA FORMATION: PERIVASCULAR GLIOMA INVASION IS A VEGF-INDEPENDENT MECHANISM OF TUMOR VASCULARIZATION Neuro-Oncology. 16: v1-v2. DOI: 10.1093/Neuonc/Nou238.4  0.593
2014 Sauderson NSR, Castro MG, Lowenstein PR. Gene Therapy From Theoretical Potential to Clinical Implementation Reference Module in Biomedical Research. DOI: 10.1016/B978-0-12-801238-3.05502-1  0.438
2013 Mineharu Y, Castro MG, Lowenstein PR, Sakai N, Miyamoto S. Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials. Neurologia Medico-Chirurgica. 53: 741-54. PMID 24140772 DOI: 10.2176/Nmc.Ra2013-0234  0.579
2013 Castro MG, Lowenstein PR. Neuro-oncology: The long and winding road--gene therapy for glioma. Nature Reviews. Neurology. 9: 609-10. PMID 24061435 DOI: 10.1038/Nrneurol.2013.198  0.531
2013 VanderVeen N, Paran C, Krasinkiewicz J, Zhao L, Palmer D, Hervey-Jumper S, Ng P, Lowenstein PR, Castro MG. Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma. Human Gene Therapy. Clinical Development. 24: 116-26. PMID 24007469 DOI: 10.1089/Humc.2013.139  0.573
2013 Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, Gray SJ, Lowenstein PR, Vandenberghe LH, Wilson TJ, Wolfe JH, Glorioso JC. Progress in gene therapy for neurological disorders. Nature Reviews. Neurology. 9: 277-91. PMID 23609618 DOI: 10.1038/Nrneurol.2013.56  0.518
2013 Puntel M, A K M GM, Farrokhi C, Vanderveen N, Paran C, Appelhans A, Kroeger KM, Salem A, Lacayo L, Pechnick RN, Kelson KR, Kaur S, Kennedy S, Palmer D, Ng P, ... ... Castro MG, et al. Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma. Toxicology and Applied Pharmacology. 268: 318-30. PMID 23403069 DOI: 10.1016/J.Taap.2013.02.001  0.557
2013 Simonato M, Bennett J, Boulis NM, Castro MG, Fink D, Goins WF, Gray SJ, Lowenstein PR, Vandenberghe L, Wilson TJ, Wolfe JH, Glorioso JC. Correction: Progress in gene therapy for neurological disorders Nature Reviews Neurology. 9: 298-298. DOI: 10.1038/Nrneurol.2013.103  0.46
2013 Sauderson NSR, Castro MG, Lowenstein PR. Gene Therapy: From Theoretical Potential to Clinical Implementation Emery and Rimoin's Principles and Practice of Medical Genetics. 1-32. DOI: 10.1016/B978-0-12-383834-6.00037-9  0.438
2013 Assi H, Candolfi M, Lowenstein PR, Castro MG. Rodent glioma models: Intracranial stereotactic allografts and xenografts Neuromethods. 77: 229-243. DOI: 10.1007/7657_2011_33  0.434
2012 Assi H, Candolfi M, Lowenstein PR, Castro MG. Rodent Glioma Models: Intracranial Stereotactic Allografts and Xenografts. Neuromethods. 77: 229-243. PMID 31462854 DOI: 10.1007/7657_2011_33  0.547
2012 Mineharu Y, Muhammad AK, Yagiz K, Candolfi M, Kroeger KM, Xiong W, Puntel M, Liu C, Levy E, Lugo C, Kocharian A, Allison JP, Curran MA, Lowenstein PR, Castro MG. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 9: 827-43. PMID 22996231 DOI: 10.1007/S13311-012-0144-7  0.614
2012 Candolfi M, King GD, Yagiz K, Curtin JF, Mineharu Y, Muhammad AK, Foulad D, Kroeger KM, Barnett N, Josien R, Lowenstein PR, Castro MG. Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics. Neoplasia (New York, N.Y.). 14: 757-70. PMID 22952428 DOI: 10.1593/Neo.12794  0.719
2012 Muhammad AK, Xiong W, Puntel M, Farrokhi C, Kroeger KM, Salem A, Lacayo L, Pechnick RN, Kelson KR, Palmer D, Ng P, Liu C, Lowenstein PR, Castro MG. Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial. Human Gene Therapy Methods. 23: 271-84. PMID 22950971 DOI: 10.1089/Hgtb.2012.060  0.554
2012 Assi H, Candolfi M, Baker G, Mineharu Y, Lowenstein PR, Castro MG. Gene therapy for brain tumors: basic developments and clinical implementation. Neuroscience Letters. 527: 71-7. PMID 22906921 DOI: 10.1016/J.Neulet.2012.08.003  0.636
2012 Sanderson NS, Puntel M, Kroeger KM, Bondale NS, Swerdlow M, Iranmanesh N, Yagita H, Ibrahim A, Castro MG, Lowenstein PR. Cytotoxic immunological synapses do not restrict the action of interferon-γ to antigenic target cells. Proceedings of the National Academy of Sciences of the United States of America. 109: 7835-40. PMID 22547816 DOI: 10.1073/Pnas.1116058109  0.523
2012 Lowenstein PR, Castro MG. Pushing the limits of glioma resection using electrophysiologic brain mapping. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2437-40. PMID 22529267 DOI: 10.1200/Jco.2011.40.6959  0.52
2012 Zirger JM, Puntel M, Bergeron J, Wibowo M, Moridzadeh R, Bondale N, Barcia C, Kroeger KM, Liu C, Castro MG, Lowenstein PR. Immune-mediated loss of transgene expression from virally transduced brain cells is irreversible, mediated by IFNγ, perforin, and TNFα, and due to the elimination of transduced cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 808-19. PMID 22233583 DOI: 10.1038/Mt.2011.243  0.59
2011 King GD, Muhammad AG, Larocque D, Kelson KR, Xiong W, Liu C, Sanderson NS, Kroeger KM, Castro MG, Lowenstein PR. Combined Flt3L/TK Gene Therapy Induces Immunological Surveillance Which Mediates an Immune Response Against a Surrogate Brain Tumor Neoantigen. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1793-1801. PMID 28160649 DOI: 10.1038/mt.2011.77  0.733
2011 Candolfi M, Curtin JF, Yagiz K, Assi H, Wibowo MK, Alzadeh GE, Foulad D, Muhammad AK, Salehi S, Keech N, Puntel M, Liu C, Sanderson NR, Kroeger KM, Dunn R, ... ... Castro MG, et al. B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia (New York, N.Y.). 13: 947-60. PMID 22028620 DOI: 10.1593/Neo.11024  0.584
2011 Puntel M, Barrett R, Sanderson NS, Kroeger KM, Bondale N, Wibowo M, Kennedy S, Liu C, Castro MG, Lowenstein PR. Identification and visualization of CD8+ T cell mediated IFN-γ signaling in target cells during an antiviral immune response in the brain. Plos One. 6: e23523. PMID 21897844 DOI: 10.1371/Journal.Pone.0023523  0.572
2011 Candolfi M, Kroeger KM, Xiong W, Liu C, Puntel M, Yagiz K, Muhammad AG, Mineharu Y, Foulad D, Wibowo M, Assi H, Baker GJ, Lowenstein PR, Castro MG. Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation. Anti-Cancer Agents in Medicinal Chemistry. 11: 729-38. PMID 21707497 DOI: 10.2174/187152011797378689  0.575
2011 Mineharu Y, King GD, Muhammad AK, Bannykh S, Kroeger KM, Liu C, Lowenstein PR, Castro MG. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4705-18. PMID 21632862 DOI: 10.1158/1078-0432.Ccr-11-0915  0.729
2011 King GD, Muhammad AK, Larocque D, Kelson KR, Xiong W, Liu C, Sanderson NS, Kroeger KM, Castro MG, Lowenstein PR. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1793-801. PMID 21505426 DOI: 10.1038/Mt.2011.77  0.753
2011 Castro MG, Candolfi M, Kroeger K, King GD, Curtin JF, Yagiz K, Mineharu Y, Assi H, Wibowo M, Ghulam Muhammad AK, Foulad D, Puntel M, Lowenstein PR. Gene therapy and targeted toxins for glioma. Current Gene Therapy. 11: 155-80. PMID 21453286  0.712
2011 Candolfi M, Yagiz K, Balasubramanian K, Puntel M, King GD, Mineharu Y, Muhammad AG, Foulad D, Barnett N, Kroeger KM, Lowenstein PR, Castro MG. Abstract 467: Circulating DNA released from brain tumors in response to conditional cytotoxic/immune stimulatory gene therapy induces activation of TLR9 on pDCs, leading to antitumor immunity Cancer Research. 71: 467-467. DOI: 10.1158/1538-7445.Am2011-467  0.73
2011 Candolfi M, Yagiz K, Assi H, Muhammad AG, Liu C, Foulad D, Alzadeh G, Pisera DA, Kroeger KM, Lowenstein PR, Castro MG. Abstract 3645: Glioma-derived factors induce the expansion of myeloid derived suppressor cells which mediate immune suppression and tumor progression Cancer Research. 71: 3645-3645. DOI: 10.1158/1538-7445.Am2011-3645  0.623
2010 Kroeger KM, Muhammad AK, Baker GJ, Assi H, Wibowo MK, Xiong W, Yagiz K, Candolfi M, Lowenstein PR, Castro MG. Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discovery Medicine. 10: 293-304. PMID 21034670  0.551
2010 Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Kroeger KM, Tesarfreund M, Lee S, Debinski W, Sareen D, Svendsen CN, ... ... Castro MG, et al. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proceedings of the National Academy of Sciences of the United States of America. 107: 20021-6. PMID 21030678 DOI: 10.1073/Pnas.1008261107  0.594
2010 Larocque D, Sanderson NS, Bergeron J, Curtin JF, Girton J, Wibowo M, Bondale N, Kroeger KM, Yang J, Lacayo LM, Reyes KC, Farrokhi C, Pechnick RN, Castro MG, Lowenstein PR. Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology. Proceedings of the National Academy of Sciences of the United States of America. 107: 14443-8. PMID 20660723 DOI: 10.1073/Pnas.0913496107  0.572
2010 Xiong W, Candolfi M, Liu C, Muhammad AK, Yagiz K, Puntel M, Moore PF, Avalos J, Young JD, Khan D, Donelson R, Pluhar GE, Ohlfest JR, Wawrowsky K, Lowenstein PR, ... Castro MG, et al. Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial. Plos One. 5: e11074. PMID 20552015 DOI: 10.1371/Journal.Pone.0011074  0.595
2010 Puntel M, Muhammad AK, Candolfi M, Salem A, Yagiz K, Farrokhi C, Kroeger KM, Xiong W, Curtin JF, Liu C, Bondale NS, Lerner J, Pechnick RN, Palmer D, Ng P, ... ... Castro MG, et al. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics. Journal of Virology. 84: 6007-17. PMID 20375153 DOI: 10.1128/Jvi.00398-10  0.593
2010 Pluhar GE, Grogan PT, Seiler C, Goulart M, Santacruz KS, Carlson C, Chen W, Olin MR, Lowenstein PR, Castro MG, Haines SJ, Ohlfest JR. Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine. 28: 3371-8. PMID 20197146 DOI: 10.1016/J.Vaccine.2010.02.082  0.575
2010 Han Y, Chang QA, Virag T, West NC, George D, Castro MG, Bohn MC. Lack of humoral immune response to the tetracycline (Tet) activator in rats injected intracranially with Tet-off rAAV vectors. Gene Therapy. 17: 616-25. PMID 20164859 DOI: 10.1038/Gt.2010.6  0.381
2010 Muhammad AK, Puntel M, Candolfi M, Salem A, Yagiz K, Farrokhi C, Kroeger KM, Xiong W, Curtin JF, Liu C, Lawrence K, Bondale NS, Lerner J, Baker GJ, Foulad D, ... ... Castro MG, et al. Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma. Clinical Pharmacology and Therapeutics. 88: 204-13. PMID 20164833 DOI: 10.1038/Clpt.2009.260  0.575
2010 Yang J, Sanderson NS, Wawrowsky K, Puntel M, Castro MG, Lowenstein PR. Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo. Proceedings of the National Academy of Sciences of the United States of America. 107: 4716-21. PMID 20133734 DOI: 10.1073/Pnas.0911587107  0.595
2010 Puntel M, Kroeger KM, Sanderson NS, Thomas CE, Castro MG, Lowenstein PR. Gene transfer into rat brain using adenoviral vectors. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit 4.24. PMID 20066657 DOI: 10.1002/0471142301.Ns0424S50  0.599
2010 Lowenstein PR, Mineharu Y, King G, Candolfi M, Xiong W, Assi H, Yagiz K, Kroeger K, Bannykh S, Castro M. Comparison of intratumoral loading of Flt3L/TK-recruited dendritic cells and systemic vaccination with tumor-lysate loaded dendritic cells in the stringent syngeneic CNS1 rat glioma model: Effect of temozolomide on anti-glioma immunity. Journal of Clinical Oncology. 28: 2093-2093. DOI: 10.1200/Jco.2010.28.15_Suppl.2093  0.713
2010 Sanderson NS, Puntel M, Baker G, Castro MG, Lowenstein PR. Abstract 4798: Cytotoxic T cells kill tumor cells in a contact and antigen-dependent manner, but the interaction affects neighboring, non-target cells via interferon gamma secretion Cancer Research. 70: 4798-4798. DOI: 10.1158/1538-7445.Am10-4798  0.583
2010 Lowenstein PR, Yang J, Sanderson N, Wawrowsky K, Castro MG. Abstract 4795: Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo Cancer Research. 70: 4795-4795. DOI: 10.1158/1538-7445.Am10-4795  0.598
2010 Castro MG, Candolfi M, Yagiz K, Kroeger KM, Foulad D, AhlZadeh GE, Tesarfreund M, Lowenstein PR. Abstract 3825: Synergistic antitumor effect of chemotherapy and immunotherapy in syngeneic brain tumor models in mice Cancer Research. 70: 3825-3825. DOI: 10.1158/1538-7445.Am10-3825  0.609
2010 Candolfi M, Curtin JF, Yagiz K, Assi H, Wibowo M, Ahlzadeh G, Foulad D, Kroeger KM, Tesarfreund M, Alden A, Liu C, Dunn R, Lowenstein P, Castro MG. Abstract 1909: B cells present tumor antigen and mediate anti-tumor immunity induced by a combined immune-stimulatory/conditional cytotoxic therapy for glioblastoma Cancer Research. 70: 1909-1909. DOI: 10.1158/1538-7445.Am10-1909  0.586
2009 Rodriguez SS, Castro MG, Brown OA, Goya RG, Console GM. GENE THERAPY FOR THE TREATMENT OF PITUITARY TUMORS. Expert Review of Endocrinology & Metabolism. 4: 359-370. PMID 20186255 DOI: 10.1586/Eem.09.16  0.428
2009 Candolfi M, Kroeger KM, Muhammad AK, Yagiz K, Farrokhi C, Pechnick RN, Lowenstein PR, Castro MG. Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Current Gene Therapy. 9: 409-21. PMID 19860655 DOI: 10.2174/156652309789753301  0.612
2009 Lowenstein PR, Castro MG. Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? Current Gene Therapy. 9: 368-74. PMID 19860651 DOI: 10.2174/156652309789753392  0.469
2009 Castro MG, Lowenstein PR. Gene therapy continues to make progress: clinical and regulatory perspectives. Current Gene Therapy. 9: 327-8. PMID 19860647 DOI: 10.2174/156652309789753374  0.515
2009 Lowenstein PR, Lowenstein ED, Castro MG. Challenges in the evaluation, consent, ethics and history of early clinical trials - Implications of the Tuskegee 'trial' for safer and more ethical clinical trials. Current Opinion in Molecular Therapeutics. 11: 481-4. PMID 19806495  0.361
2009 Ghulam Muhammad AK, Candolfi M, King GD, Yagiz K, Foulad D, Mineharu Y, Kroeger KM, Treuer KA, Nichols WS, Sanderson NS, Yang J, Khayznikov M, Van Rooijen N, Lowenstein PR, Castro MG. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6113-27. PMID 19789315 DOI: 10.1158/1078-0432.Ccr-09-1087  0.738
2009 Vit JP, Ohara PT, Sundberg C, Rubi B, Maechler P, Liu C, Puntel M, Lowenstein P, Castro M, Jasmin L. Adenovector GAD65 gene delivery into the rat trigeminal ganglion produces orofacial analgesia Molecular Pain. 5. PMID 19656360 DOI: 10.1186/1744-8069-5-42  0.479
2009 Barcia C, Gómez A, Gallego-Sanchez JM, Perez-Vallés A, Castro MG, Lowenstein PR, Barcia C, Herrero MT. Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells. The American Journal of Pathology. 175: 786-98. PMID 19628762 DOI: 10.2353/Ajpath.2009.081034  0.565
2009 Candolfi M, Yagiz K, Foulad D, Alzadeh GE, Tesarfreund M, Muhammad AK, Puntel M, Kroeger KM, Liu C, Lee S, Curtin JF, King GD, Lerner J, Sato K, Mineharu Y, ... ... Castro MG, et al. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4401-14. PMID 19570774 DOI: 10.1158/1078-0432.Ccr-09-0155  0.682
2009 Wu R, Wang H, Xia X, Zhou H, Liu C, Castro M, Xu Z. Nerve injection of viral vectors efficiently transfers transgenes into motor neurons and delivers RNAi therapy against ALS Antioxidants and Redox Signaling. 11: 1523-1534. PMID 19344276 DOI: 10.1089/Ars.2009.2618  0.345
2009 Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, Liu C, Muhammad AK, Clark MC, Arditi M, Comin-Anduix B, Ribas A, ... ... Castro MG, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. Plos Medicine. 6: e10. PMID 19143470 DOI: 10.1371/Journal.Pmed.1000010  0.625
2009 Puntel M, Barrett RJ, Mondkar S, Saxena V, Kroeger KM, Muhammad AK, Liu C, Bondale N, Sciascia S, Xiong W, Shi Y, Salem A, Zadmehr A, Huynh P, Palmer D, ... ... Castro MG, et al. Herpes simplex virus type 1 thymidine kinase sequence fused to the lacz gene increases levels of {beta}-galactosidase activity per genome of high-capacity but not first-generation adenoviral vectors in vitro and in vivo. Journal of Virology. 83: 2004-10. PMID 19073729 DOI: 10.1128/Jvi.01298-08  0.523
2009 Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, Liu C, Muhammad AKMG, Clark MC, Arditi M, Comin-Anduix B, Ribas A, ... ... Castro MG, et al. HMGB1 Is Released into the Supernatant of GL26, LLc1, GL261, and B16-F10 Tumor Cell Lines in Response to Treatment with Ad-TK (+GCV), Irradiation, or Temozolomide Plos Medicine. DOI: 10.1371/Journal.Pmed.1000010.G009  0.521
2008 King GD, Kroeger KM, Bresee CJ, Candolfi M, Liu C, Manalo CM, Muhammad AG, Pechnick RN, Lowenstein PR, Castro MG. Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumor-induced Behavioral Deficits. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 682-690. PMID 28178463 DOI: 10.1038/Mt.2008.18  0.733
2008 Southgate T, Kroeger KM, Liu C, Lowenstein PR, Castro MG. Gene transfer into neural cells in vitro using adenoviral vectors. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit 4.23. PMID 18972378 DOI: 10.1002/0471142301.Ns0423S45  0.546
2008 Barcia C, Sanderson NS, Barrett RJ, Wawrowsky K, Kroeger KM, Puntel M, Liu C, Castro MG, Lowenstein PR. T cells' immunological synapses induce polarization of brain astrocytes in vivo and in vitro: a novel astrocyte response mechanism to cellular injury. Plos One. 3: e2977. PMID 18714338 DOI: 10.1371/Journal.Pone.0002977  0.53
2008 Barcia C, Gomez A, de Pablos V, Fernández-Villalba E, Liu C, Kroeger KM, Martín J, Barreiro AF, Castro MG, Lowenstein PR, Herrero MT. CD20, CD3, and CD40 ligand microclusters segregate three-dimensionally in vivo at B-cell-T-cell immunological synapses after viral immunity in primate brain. Journal of Virology. 82: 9978-93. PMID 18684835 DOI: 10.1128/Jvi.01326-08  0.527
2008 Curtin JF, Candolfi M, Puntel M, Xiong W, Muhammad AK, Kroeger K, Mondkar S, Liu C, Bondale N, Lowenstein PR, Castro MG. Regulated expression of adenoviral vectors-based gene therapies: therapeutic expression of toxins and immune-modulators. Methods in Molecular Biology (Clifton, N.J.). 434: 239-66. PMID 18470649 DOI: 10.1007/978-1-60327-248-3_15  0.574
2008 Curtin JF, Candolfi M, Fakhouri TM, Liu C, Alden A, Edwards M, Lowenstein PR, Castro MG. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. Plos One. 3: e1983. PMID 18431473 DOI: 10.1371/Journal.Pone.0001983  0.605
2008 Curtin JF, Candolfi M, Xiong W, Lowenstein PR, Castro MG. Turning the gene tap off; implications of regulating gene expression for cancer therapeutics. Molecular Cancer Therapeutics. 7: 439-48. PMID 18347132 DOI: 10.1158/1535-7163.Mct-07-2328  0.569
2008 King GD, Muhammad AK, Xiong W, Kroeger KM, Puntel M, Larocque D, Palmer D, Ng P, Lowenstein PR, Castro MG. High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. Journal of Virology. 82: 4680-4. PMID 18287240 DOI: 10.1128/Jvi.00232-08  0.747
2008 King GD, Kroeger KM, Bresee CJ, Candolfi M, Liu C, Manalo CM, Muhammad AK, Pechnick RN, Lowenstein PR, Castro MG. Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 682-90. PMID 18283279 DOI: 10.1038/mt.2008.18  0.712
2008 Barcia C, Wawrowsky K, Barrett RJ, Liu C, Castro MG, Lowenstein PR. In vivo polarization of IFN-gamma at Kupfer and non-Kupfer immunological synapses during the clearance of virally infected brain cells. Journal of Immunology (Baltimore, Md. : 1950). 180: 1344-52. PMID 18209028 DOI: 10.4049/Jimmunol.180.3.1344  0.506
2008 Xiong W, Candolfi M, Kroeger KM, Puntel M, Mondkar S, Larocque D, Liu C, Curtin JF, Palmer D, Ng P, Lowenstein PR, Castro MG. Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 343-51. PMID 18180781 DOI: 10.1038/Sj.Mt.6300375  0.567
2008 King GD, Muhammad AK, Curtin JF, Barcia C, Puntel M, Liu C, Honig SB, Candolfi M, Mondkar S, Lowenstein PR, Castro MG. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro-Oncology. 10: 19-31. PMID 18079358 DOI: 10.1215/15228517-2007-045  0.734
2008 Jasmin L, Vit J, Puntel M, Liu C, Castro M, Lowenstein P, Ohara P. Adenovirus-mediated Expression of GAD65 into the Trigeminal Ganglion Produces Long-lasting Analgesia Neurosurgery. 62: 1427-1428. DOI: 10.1227/01.Neu.0000333537.61406.71  0.487
2008 King GD, Muhammad AKMG, Xiong W, Kroeger KM, Puntel M, Larocque D, Palmer D, Ng P, Lowenstein PR, Castro MG. High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity (Journal of Virology (2008) 82, 9, (4680-4684)) Journal of Virology. 82: 6087. DOI: 10.1128/Jvi.00828-08  0.708
2008 Curtin JF, Fakhouri TM, Candolfi M, Alden A, Edwards MR, Liu C, Lowenstein PR, Castro MG. Depletion of CD25+ T cells inhibits CD8+ T cells clonal expansion and glioblastoma multiforme regression. The Faseb Journal. 22: 514-514. DOI: 10.1096/Fasebj.22.2_Supplement.514  0.468
2008 Lowenstein PR, Koreger KM, Castro MG. Viral gene therapy for central nervous system diseases Neurotropic Viral Infections. 424-434. DOI: 10.1017/CBO9780511541728.028  0.451
2007 Lowenstein PR, Mandel RJ, Xiong WD, Kroeger K, Castro MG. Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Current Gene Therapy. 7: 347-60. PMID 17979681 DOI: 10.2174/156652307782151498  0.596
2007 Lowenstein PR, Kroeger K, Castro MG. Immunology of neurological gene therapy: how T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 4: 715-24. PMID 17920552 DOI: 10.1016/J.Nurt.2007.07.010  0.606
2007 Barcia C, Jimenez-Dalmaroni M, Kroeger KM, Puntel M, Rapaport AJ, Larocque D, King GD, Johnson SA, Liu C, Xiong W, Candolfi M, Mondkar S, Ng P, Palmer D, Castro MG, et al. One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 2154-63. PMID 17895861 DOI: 10.1038/Sj.Mt.6300305  0.721
2007 Oh S, Odland R, Wilson SR, Kroeger KM, Liu C, Lowenstein PR, Castro MG, Hall WA, Ohlfest JR. Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. Journal of Neurosurgery. 107: 568-77. PMID 17886557 DOI: 10.3171/Jns-07/09/0568  0.516
2007 Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE, McNiel EA, Ohlfest JR, Freese AB, Moore PF, Lerner J, Lowenstein PR, Castro MG. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. Journal of Neuro-Oncology. 85: 133-48. PMID 17874037 DOI: 10.1007/S11060-007-9400-9  0.73
2007 Oh S, Pluhar GE, McNeil EA, Kroeger KM, Liu C, Castro MG, Lowenstein PR, Freese A, Ohlfest JR. Efficacy of nonviral gene transfer in the canine brain. Journal of Neurosurgery. 107: 136-44. PMID 17639883 DOI: 10.3171/Jns-07/07/0136  0.561
2007 Candolfi M, Pluhar GE, Kroeger K, Puntel M, Curtin J, Barcia C, Muhammad AK, Xiong W, Liu C, Mondkar S, Kuoy W, Kang T, McNeil EA, Freese AB, Ohlfest JR, ... ... Castro MG, et al. Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro-Oncology. 9: 245-58. PMID 17522335 DOI: 10.1215/15228517-2007-012  0.605
2007 Candolfi M, Kroeger KM, Pluhar GE, Bergeron J, Puntel M, Curtin JF, McNiel EA, Freese AB, Ohlfest JR, Moore P, Lowenstein PR, Castro MG. Adenoviral-mediated gene transfer into the canine brain in vivo. Neurosurgery. 60: 167-77; discussion 1. PMID 17228266 DOI: 10.1227/01.Neu.0000249210.89096.6C  0.616
2007 Lowenstein PR, Castro MG. Immune Responses to Viral Vectors Injected Systemically or into the CNS Concepts in Genetic Medicine. 167-179. DOI: 10.1002/9780470184585.ch14  0.442
2007 Lowenstein PR, Castro MG. The Brain as a Target for Gene Therapy Concepts in Genetic Medicine. 153-165. DOI: 10.1002/9780470184585.ch13  0.477
2006 Barcia C, Gerdes C, Xiong WD, Thomas CE, Liu C, Kroeger KM, Castro MG, Lowenstein PR. Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells. Neuron Glia Biology. 2: 309-22. PMID 18084640 DOI: 10.1017/S1740925X07000579  0.593
2006 Zirger JM, Liu C, Barcia C, Castro MG, Lowenstein PR. Immune regulation of transgene expression in the brain: B cells regulate an early phase of elimination of transgene expression from adenoviral vectors. Viral Immunology. 19: 508-17. PMID 16987068 DOI: 10.1089/Vim.2006.19.508  0.587
2006 Barcia C, Thomas CE, Curtin JF, King GD, Wawrowsky K, Candolfi M, Xiong WD, Liu C, Kroeger K, Boyer O, Kupiec-Weglinski J, Klatzmann D, Castro MG, Lowenstein PR. In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain. The Journal of Experimental Medicine. 203: 2095-107. PMID 16923851 DOI: 10.1084/Jem.20060420  0.691
2006 Candolfi M, Curtin JF, Xiong WD, Kroeger KM, Liu C, Rentsendorj A, Agadjanian H, Medina-Kauwe L, Palmer D, Ng P, Lowenstein PR, Castro MG. Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 14: 371-81. PMID 16798098 DOI: 10.1016/J.Ymthe.2006.05.006  0.579
2006 Candolfi M, Jaita G, Pisera D, Ferrari L, Barcia C, Liu C, Yu J, Liu G, Castro MG, Seilicovich A. Adenoviral vectors encoding tumor necrosis factor-alpha and FasL induce apoptosis of normal and tumoral anterior pituitary cells. The Journal of Endocrinology. 189: 681-90. PMID 16731798 DOI: 10.1677/Joe.1.06594  0.34
2006 Puntel M, Curtin JF, Zirger JM, Muhammad AK, Xiong W, Liu C, Hu J, Kroeger KM, Czer P, Sciascia S, Mondkar S, Lowenstein PR, Castro MG. Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction. Human Gene Therapy. 17: 531-44. PMID 16716110 DOI: 10.1089/Hum.2006.17.531  0.531
2006 Zirger JM, Barcia C, Liu C, Puntel M, Mitchell N, Campbell I, Castro M, Lowenstein PR. Rapid upregulation of interferon-regulated and chemokine mRNAs upon injection of 108 international units, but not lower doses, of adenoviral vectors into the brain. Journal of Virology. 80: 5655-9. PMID 16699048 DOI: 10.1128/Jvi.00166-06  0.535
2006 Curtin JF, King GD, Barcia C, Liu C, Hubert FX, Guillonneau C, Josien R, Anegon I, Lowenstein PR, Castro MG. Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. Journal of Immunology (Baltimore, Md. : 1950). 176: 3566-77. PMID 16517725 DOI: 10.4049/Jimmunol.176.6.3566  0.696
2006 Xiong W, Goverdhana S, Sciascia SA, Candolfi M, Zirger JM, Barcia C, Curtin JF, King GD, Jaita G, Liu C, Kroeger K, Agadjanian H, Medina-Kauwe L, Palmer D, Ng P, ... ... Castro MG, et al. Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. Journal of Virology. 80: 27-37. PMID 16352528 DOI: 10.1128/Jvi.80.1.27-37.2006  0.712
2006 Puntel M, Curtin JF, Zirger JM, Muhammad A, Weidong X, Liu C, Hu J, Kroeger KM, Czer P, Sciascia S, Lowenstein PR, Castro MG. 851. Molecular Determination of High-Capacity Helper Dependent Adenoviral Vector Genomes In Vitro and In Vivo Molecular Therapy. 13: S328. DOI: 10.1016/J.Ymthe.2006.08.937  0.538
2006 King GD, Curtin JF, Liu C, Bresee C, Honig SB, Zirger JM, VanRooijen N, Ribas A, Pechnick R, Lowenstein PR, Castro MG. 621. Immunological Memory in a Syngeneic Model of Recurrent and Multifocal Glioblastoma Molecular Therapy. 13: S239. DOI: 10.1016/J.Ymthe.2006.08.696  0.744
2006 Curtin JF, King GD, Candolfi M, Liu C, Michelsen KS, Arditi M, Fakhouri TM, Comin-Anduix B, Ribas A, Lowenstein PR, Castro MG. 424. Myd88/TLR Signaling Is Required for Immunotherapy-Mediated Glioblastoma Regression Molecular Therapy. 13: S163. DOI: 10.1016/J.Ymthe.2006.08.489  0.733
2006 Candolfi M, Curtin JF, Xiong W, Kroeger KM, Liu C, Rentsendorj A, Agadjanian H, Medina-Kauwe L, Ng P, Palmer D, Lowenstein PR, Castro MG. 147. Effective Gene Transfer to Human Glioma Cells Using High Capacity Adenoviral Vectors: Human Glioma Cells Express Substantial Levels of CAR and Integrin Adenoviral Co-Receptors Molecular Therapy. 13: S58. DOI: 10.1016/J.Ymthe.2006.08.168  0.588
2006 Barcia C, Thomas C, Curtin JF, King GD, Wawrowsky K, Candolfi M, Xiong W, Chunyan L, Kroeger K, Boyer O, Kupiec-Weglinski J, Klatzmann D, Castro MG, Lowenstein PR. 999. Mature Effector Immunological Synapses Forming SMAC Mediate Clearance of Virally Infected Astrocytes from the Brain In Vivo Molecular Therapy. 13: S385. DOI: 10.1016/J.Ymthe.2006.08.1092  0.678
2006 Zirger JM, Barcia C, Bergeron J, Lui C, Castro MG, Lowenstein PR. 982. Adaptive Immune System Down-Regulates Transgene Expression from Adenovirally Infected Neurons in the Brain In Vivo Molecular Therapy. 13: S378. DOI: 10.1016/J.Ymthe.2006.08.1075  0.589
2006 Jacobs AH, Winkler A, Castro MG, Lowenstein P. Human gene therapy and imaging in neurological diseases European Journal of Nuclear Medicine and Molecular Imaging. 33: 390-390. DOI: 10.1007/S00259-005-1985-7  0.49
2005 Seilicovich A, Pisera D, Sciascia SA, Candolfi M, Puntel M, Xiong W, Jaita G, Castro MG. Gene therapy for pituitary tumors. Current Gene Therapy. 5: 559-72. PMID 16457646 DOI: 10.2174/156652305774964721  0.439
2005 King GD, Curtin JF, Candolfi M, Kroeger K, Lowenstein PR, Castro MG. Gene therapy and targeted toxins for glioma. Current Gene Therapy. 5: 535-57. PMID 16457645 DOI: 10.2174/156652305774964631  0.734
2005 Jacobs AH, Winkler A, Castro MG, Lowenstein P. Human gene therapy and imaging in neurological diseases. European Journal of Nuclear Medicine and Molecular Imaging. 32: S358-83. PMID 16328505 DOI: 10.1007/S00259-005-1960-3  0.499
2005 Torres EM, Monville C, Lowenstein PR, Castro MG, Dunnett SB. Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease using adenoviral vectors Increased yield of dopamine cells is dependent on embryonic donor age. Brain Research Bulletin. 68: 31-41. PMID 16325002 DOI: 10.1016/J.Brainresbull.2005.08.021  0.475
2005 Iannacone M, Sitia G, Isogawa M, Marchese P, Castro MG, Lowenstein PR, Chisari FV, Ruggeri ZM, Guidotti LG. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nature Medicine. 11: 1167-9. PMID 16258538 DOI: 10.1038/nm1317  0.447
2005 Curtin JF, King GD, Candolfi M, Greeno RB, Kroeger KM, Lowenstein PR, Castro MG. Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Current Topics in Medicinal Chemistry. 5: 1151-70. PMID 16248789 DOI: 10.2174/156802605774370856  0.752
2005 Ali S, King GD, Curtin JF, Candolfi M, Xiong W, Liu C, Puntel M, Cheng Q, Prieto J, Ribas A, Kupiec-Weglinski J, van Rooijen N, Lassmann H, Lowenstein PR, Castro MG. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Research. 65: 7194-204. PMID 16103070 DOI: 10.1158/0008-5472.Can-04-3434  0.733
2005 Jaita G, Candolfi M, Zaldivar V, Zárate S, Ferrari L, Pisera D, Castro MG, Seilicovich A. Estrogens up-regulate the Fas/FasL apoptotic pathway in lactotropes. Endocrinology. 146: 4737-44. PMID 16099864 DOI: 10.1210/En.2005-0279  0.316
2005 Abordo-Adesida E, Follenzi A, Barcia C, Sciascia S, Castro MG, Naldini L, Lowenstein PR. Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Human Gene Therapy. 16: 741-51. PMID 15960605 DOI: 10.1089/Hum.2005.16.741  0.563
2005 Torres EM, Monville C, Lowenstein PR, Castro MG, Dunnett SB. In vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system. Brain Research. Molecular Brain Research. 137: 1-10. PMID 15950755 DOI: 10.1016/J.Molbrainres.2004.10.046  0.52
2005 Goverdhana S, Puntel M, Xiong W, Zirger JM, Barcia C, Curtin JF, Soffer EB, Mondkar S, King GD, Hu J, Sciascia SA, Candolfi M, Greengold DS, Lowenstein PR, Castro MG. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Molecular Therapy : the Journal of the American Society of Gene Therapy. 12: 189-211. PMID 15946903 DOI: 10.1016/J.Ymthe.2005.03.022  0.7
2005 Barcia C, Thomas C, Curtin JF, Zirger JM, Xiong W, Boyer O, Klatzmann D, Castro MG, Lowenstein PR. 946. CD8+ T Cells Are Partially Mediate the Immune-Mediated Silencing of Adenoviral Vector-Encoded Transgene Expression in the Rat Brain Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.489  0.602
2005 Zirger JM, Barcia C, Liu C, Castro M, Lowenstein P. 745. CD4-T Cell Responses Mediated by IFN|[gamma]| and Perforin Eliminate Adenoviral-Mediated Transgene Expression from the CNS of Mice by Cytolytic and Non-Cytolytic Mechanisms Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.285  0.584
2005 Barcia C, Zirger JM, Xiong W, Ng P, Palmer D, Castro MG, Lowenstein PR. 430. Immune System Regulation of Transgene Expression from High-Capacity Gutless Adenoviral Vectors in the Mouse Brain: Very Long Term Expression Following Pre-Immunization Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.432  0.562
2005 Xiong W, Goverdhana S, Curtin JF, Barcia-Gonzalez C, Zirger JM, King GD, Sciascia SA, Puntel M, Candolfi M, Palmer D, Ng P, Lowenstein PR, Castro MG. 143. Regulated, High Capacity Adenoviral Vectors Mediated Long-Term Gene Expression in the Brain Even in the Presence of a Peripheral Immune Response to Adenovirus Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.148  0.72
2004 Suwelack D, Hurtado-Lorenzo A, Millan E, Gonzalez-Nicolini V, Wawrowsky K, Lowenstein PR, Castro MG. Neuronal expression of the transcription factor Gli1 using the Talpha1 alpha-tubulin promoter is neuroprotective in an experimental model of Parkinson's disease. Gene Therapy. 11: 1742-52. PMID 15573088 DOI: 10.1038/Sj.Gt.3302377  0.502
2004 Ali S, Curtin JF, Zirger JM, Xiong W, King GD, Barcia C, Liu C, Puntel M, Goverdhana S, Lowenstein PR, Castro MG. Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 1071-84. PMID 15564139 DOI: 10.1016/J.Ymthe.2004.08.025  0.751
2004 Biglari A, Bataille D, Naumann U, Weller M, Zirger J, Castro MG, Lowenstein PR. Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Therapy. 11: 721-32. PMID 15475879 DOI: 10.1038/Sj.Cgt.7700783  0.614
2004 Hurtado-Lorenzo A, Millan E, Gonzalez-Nicolini V, Suwelack D, Castro MG, Lowenstein PR. Differentiation and transcription factor gene therapy in experimental parkinson's disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 507-24. PMID 15336651 DOI: 10.1016/J.Ymthe.2004.05.021  0.515
2004 Dorigo O, Gil JS, Gallaher SD, Tan BT, Castro MG, Lowenstein PR, Calos MP, Berk AJ. Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. Journal of Virology. 78: 6556-66. PMID 15163748 DOI: 10.1128/Jvi.78.12.6556-6566.2004  0.551
2004 Lowenstein PR, Castro MG. Recent advances in the pharmacology of neurological gene therapy. Current Opinion in Pharmacology. 4: 91-7. PMID 15018845 DOI: 10.1016/J.Coph.2003.10.005  0.576
2004 Zirger JM, Barcia C, Liu C, Puntel M, Sitia G, Guidotti L, Mitchell N, Campbell I, Castro MG, Lowenstein PR. 1019. Immune System Regulation of Transgene Expression in the Brain 2: Differential Increase of mRNAs Encoding for Interferon-Regulated, Chemokine, and T-Cell Genes during Either Innate Acute or Chronic Systemic Adaptive Immune Responses to First Generation Adenoviral Vectors Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.964  0.575
2004 Goverdhana S, Xiong W, Greengold DS, Curtin J, Soffer E, Lowenstein PR, Castro MG. 790. Regulatable Transgene Expression from Gutless Adenoviral Vectors Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.880  0.531
2004 Lowenstein PR, Abordo-Adesida E, Barcia C, Follenzi A, Naldini L, Castro MG. 661. Immune System Regulation of Transgene Expression in the Brain 3: Effects of the Immune Response on Transgene Expression from HIV-Derived Lentiviral Vectors Injected into the Rat Striatum Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.607  0.578
2004 Barcia C, Thomas C, Zirger J, Xiong W, Boyer O, Klatzmann D, Castro MG, Lowenstein PR. 459. Immune System Regulation of Transgene Expression in the Brain 1: Systemically Activated Immune Responses Silence Adenoviral Vector-Encoded Transgene Expression in the Brain Through Both Non-Cytolytic, and Cytotoxic Mechanisms Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.423  0.579
2003 Kingston PA, Sinha S, Appleby CE, David A, Verakis T, Castro MG, Lowenstein PR, Heagerty AM. Adenovirus-mediated gene transfer of transforming growth factor-beta3, but not transforming growth factor-beta1, inhibits constrictive remodeling and reduces luminal loss after coronary angioplasty. Circulation. 108: 2819-25. PMID 14638551 DOI: 10.1161/01.Cir.0000097068.49080.A0  0.445
2003 Lowenstein PR, Suwelack D, Hu J, Yuan X, Jimenez-Dalmaroni M, Goverdhana S, Castro MG. Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders. International Review of Neurobiology. 55: 3-64. PMID 12968530 DOI: 10.1016/S0074-7742(03)01001-8  0.581
2003 Stone D, Xiong W, Williams JC, David A, Lowenstein PR, Castro MG. Adenovirus expression of IL-1 and NF-kappaB inhibitors does not inhibit acute adenoviral-induced brain inflammation, but delays immune system-mediated elimination of transgene expression. Molecular Therapy : the Journal of the American Society of Gene Therapy. 8: 400-11. PMID 12946313 DOI: 10.1016/S1525-0016(03)00178-3  0.545
2003 Appleby CE, Kingston PA, David A, Gerdes CA, Umaña P, Castro MG, Lowenstein PR, Heagerty AM. A novel combination of promoter and enhancers increases transgene expression in vascular smooth muscle cells in vitro and coronary arteries in vivo after adenovirus-mediated gene transfer. Gene Therapy. 10: 1616-22. PMID 12907954 DOI: 10.1038/Sj.Gt.3302044  0.534
2003 Stirland JA, Seymour ZC, Windeatt S, Norris AJ, Stanley P, Castro MG, Loudon AS, White MR, Davis JR. Real-time imaging of gene promoter activity using an adenoviral reporter construct demonstrates transcriptional dynamics in normal anterior pituitary cells. The Journal of Endocrinology. 178: 61-9. PMID 12844337 DOI: 10.1677/Joe.0.1780061  0.371
2003 Lowenstein PR, Castro MG. Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences. Gene Therapy. 10: 946-54. PMID 12756415 DOI: 10.1038/Sj.Gt.3302048  0.528
2003 Castro MG, Cowen R, Williamson IK, David A, Jimenez-Dalmaroni MJ, Yuan X, Bigliari A, Williams JC, Hu J, Lowenstein PR. Current and future strategies for the treatment of malignant brain tumors. Pharmacology & Therapeutics. 98: 71-108. PMID 12667889 DOI: 10.1016/S0163-7258(03)00014-7  0.601
2003 Castro M, Goverdhana S, Hu J, Jovel N, Yuan X, Lowenstein P. Gene therapy for pituitary tumors: from preclinical models to clinical implementation Frontiers in Neuroendocrinology. 24: 62-77. PMID 12609500 DOI: 10.1016/S0091-3022(02)00106-1  0.591
2003 Hurtado-Lorenzo A, David A, Thomas C, Castro MG, Lowenstein PR. Use of recombinant adenovirus for gene transfer into the rat brain. Evaluation of gene transfer efficiency, toxicity, and inflammatory and immune reactions. Methods in Molecular Medicine. 76: 113-33. PMID 12526161 DOI: 10.1385/1-59259-304-6:113  0.522
2003 Guillot C, Ménoret S, Guillonneau C, Braudeau C, Castro MG, Lowenstein P, Anegon I. Active suppression of allogeneic proliferative responses by dendritic cells after induction of long-term allograft survival by CTLA4Ig. Blood. 101: 3325-33. PMID 12515725 DOI: 10.1182/Blood-2002-07-2076  0.533
2003 Solly SK, Trajcevski S, Frisén C, Holzer GW, Nelson E, Clerc B, Abordo-Adesida E, Castro M, Lowenstein P, Klatzmann D. Replicative retroviral vectors for cancer gene therapy. Cancer Gene Therapy. 10: 30-9. PMID 12489026 DOI: 10.1038/Sj.Cgt.7700521  0.581
2003 Castro MG, Xiong W, Goverdhana S, Greengold D, Lowenstein PR. Gene therapy for pituitary tumors Endocrinologist. 13: 351-357. DOI: 10.1097/01.Ten.0000084309.68121.84  0.575
2002 Cowen RL, Williams JC, Emery S, Blakey D, Darling JL, Lowenstein PR, Castro MG. Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane. Cancer Gene Therapy. 9: 897-907. PMID 12386828 DOI: 10.1038/Sj.Cgt.7700514  0.567
2002 Mohammad YN, Perone M, Wang L, Ingleton PM, Castro MG, Lovejoy DA. Expression of prolactin receptors and regulation of cell proliferation by prolactin, corticotropin-releasing factor, and corticosterone in a neuroblastoma cell line. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 80: 475-82. PMID 12234101 DOI: 10.1139/O02-036  0.306
2002 Lowenstein PR, Castro MG. Progress and challenges in viral vector-mediated gene transfer to the brain. Current Opinion in Molecular Therapeutics. 4: 359-71. PMID 12222874  0.541
2002 Grande-Pérez A, Sierra S, Castro MG, Domingo E, Lowenstein PR. Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proceedings of the National Academy of Sciences of the United States of America. 99: 12938-43. PMID 12215495 DOI: 10.1073/Pnas.182426999  0.457
2002 Mathieu P, Guillot C, Gerdes C, Buzelin F, Lowenstein P, Castro M, Soulillou JP, Anegon I. Adenovirus-mediated CD40Ig expression attenuates chronic vascular rejection lesions in an aorta allotransplantation model. Transplantation Proceedings. 34: 743-744. PMID 12034168 DOI: 10.1016/S0041-1345(01)02899-8  0.513
2002 Davis JR, McMahon RF, Lowenstein PR, Castro MG, Lincoln GA, McNeilly AS. Adenovirus-mediated gene transfer in the ovine pituitary gland is associated with hypophysitis. The Journal of Endocrinology. 173: 265-71. PMID 12010634 DOI: 10.1677/Joe.0.1730265  0.533
2002 Thomas CE, Edwards P, Wickham TJ, Castro MG, Lowenstein PR. Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types. Journal of Virology. 76: 3452-60. PMID 11884569 DOI: 10.1128/Jvi.76.7.3452-3460.2002  0.539
2002 Lowenstein PR, Thomas CE, Umana P, Gerdes CA, Verakis T, Boyer O, Tondeur S, Klatzmann D, Castro MG. High-capacity, helper-dependent, "gutless" adenoviral vectors for gene transfer into brain. Methods in Enzymology. 346: 292-311. PMID 11883074 DOI: 10.1016/S0076-6879(02)46062-4  0.53
2002 Guillot C, Guillonneau C, Mathieu P, Gerdes CA, Ménoret S, Braudeau C, Tesson L, Renaudin K, Castro MG, Löwenstein PR, Anegon I. Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection. Journal of Immunology (Baltimore, Md. : 1950). 168: 1600-9. PMID 11823487 DOI: 10.4049/Jimmunol.168.4.1600  0.303
2002 Southgate T, Bain D, Fairbanks LD, Morelli A, Larregina A, Simmonds HA, Castro M, Lowenstein P. Adenoviruses encoding HPRT correct the biochemical abnormalities fully only in HPRT-deficient human cell lines: importance of species differences. Advances in Experimental Medicine and Biology. 486: 35-40. PMID 11783514 DOI: 10.1007/0-306-46843-3_7  0.523
2002 Williams JC, Stone D, Smith-Arica JR, Morris ID, Lowenstein PR, Castro MG. Erratum: Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas (Molecular Therapy (2001) vol. 4 (593-602)) Molecular Therapy. 5. DOI: 10.1006/Mthe.2001.0536  0.499
2001 Southgate TD, Kingston PA, Castro MG. Gene transfer into neural cells in vitro using adenoviral vectors. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit 4.23. PMID 18428483 DOI: 10.1002/0471142301.Ns0423S13  0.385
2001 Williams JC, Stone D, Smith-Arica JR, Morris ID, Lowenstein PR, Castro MG. Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas. Molecular Therapy : the Journal of the American Society of Gene Therapy. 4: 593-602. PMID 11735344 DOI: 10.1006/Mthe.2001.0499  0.529
2001 Kingston PA, Sinha S, David A, Castro MG, Lowenstein PR, Heagerty AM. Adenovirus-mediated gene transfer of a secreted transforming growth factor-beta type II receptor inhibits luminal loss and constrictive remodeling after coronary angioplasty and enhances adventitial collagen deposition. Circulation. 104: 2595-601. PMID 11714656  0.41
2001 Zermansky AJ, Bolognani F, Stone D, Cowsill CM, Morrissey G, Castro MG, Löwenstein PR. Towards global and long-term neurological gene therapy: unexpected transgene dependent, high-level, and widespread distribution of HSV-1 thymidine kinase throughout the CNS. Molecular Therapy : the Journal of the American Society of Gene Therapy. 4: 490-8. PMID 11708886 DOI: 10.1006/Mthe.2001.0479  0.375
2001 Castro MG, David A, Hurtado-Lorenzo A, Suwelack D, Millan E, Verakis T, Xiong WD, Yuan XP, Lowenstein PR. Gene therapy for Parkinson's disease: recent achievements and remaining challenges. Histology and Histopathology. 16: 1225-38. PMID 11642742  0.518
2001 Maleniak TC, Darling JL, Lowenstein PR, Castro MG. Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU. Cancer Gene Therapy. 8: 589-98. PMID 11571537 DOI: 10.1038/Sj.Cgt.7700348  0.569
2001 Lowenstein PR, Castro MG. Genetic engineering within the adult brain: implications for molecular approaches to behavioral neuroscience. Physiology & Behavior. 73: 833-9. PMID 11566216 DOI: 10.1016/S0031-9384(01)00520-0  0.533
2001 Castro M, Hurtado-Lorenzo A, Umana P, Smith-Arica JR, Zermansky A, Abordo-Adesida E, Löwenstein PR. Regulatable and cell-type specific transgene expression in glial cells: prospects for gene therapy for neurological disorders. Progress in Brain Research. 132: 655-81. PMID 11545027 DOI: 10.1016/S0079-6123(01)32109-X  0.38
2001 Umaña P, Gerdes CA, Stone D, Davis JR, Ward D, Castro MG, Lowenstein PR. Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nature Biotechnology. 19: 582-5. PMID 11385466 DOI: 10.1038/89349  0.499
2001 Smith-Arica JR, Williams JC, Stone D, Smith J, Lowenstein PR, Castro MG. Switching on and off transgene expression within lactotrophic cells in the anterior pituitary gland in vivo. Endocrinology. 142: 2521-32. PMID 11356701 DOI: 10.1210/Endo.142.6.8183  0.57
2001 Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR. Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Human Gene Therapy. 12: 839-46. PMID 11339900 DOI: 10.1089/104303401750148829  0.573
2001 Glaser T, Castro MG, Löwenstein PR, Weller M. Death receptor-independent cytochrome c release and caspase activation mediate thymidine kinase plus ganciclovir-mediated cytotoxicity in LN-18 and LN-229 human malignant glioma cells. Gene Therapy. 8: 469-76. PMID 11313826 DOI: 10.1038/Sj.Gt.3301415  0.39
2001 Stirland JA, Johnston JD, Cagampang FR, Morgan PJ, Castro MG, White MR, Davis JR, Loudon AS. Photoperiodic regulation of prolactin gene expression in the Syrian hamster by a pars tuberalis-derived factor. Journal of Neuroendocrinology. 13: 147-57. PMID 11168840 DOI: 10.1046/J.1365-2826.2001.00611.X  0.343
2001 Castro MG, Southgate T, Lowenstein PR. Molecular therapy in a model neuroendocrine disease: developing clinical gene therapy for pituitary tumours. Trends in Endocrinology and Metabolism: Tem. 12: 58-64. PMID 11167123 DOI: 10.1016/S1043-2760(00)00358-1  0.531
2001 Thomas CE, Birkett D, Anozie I, Castro MG, Lowenstein PR. Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Molecular Therapy : the Journal of the American Society of Gene Therapy. 3: 36-46. PMID 11162309 DOI: 10.1006/Mthe.2000.0224  0.515
2001 Davis JR, McVerry J, Lincoln GA, Windeatt S, Lowenstein PR, Castro MG, McNeilly AS. Cell type-specific adenoviral transgene expression in the intact ovine pituitary gland after stereotaxic delivery: an in vivo system for long-term multiple parameter evaluation of human pituitary gene therapy. Endocrinology. 142: 795-801. PMID 11159852 DOI: 10.1210/Endo.142.2.7963  0.589
2001 Southgate TD, Stone D, Williams JC, Lowenstein PR, Castro MG. Long-term transgene expression within the anterior pituitary gland in situ: impact on circulating hormone levels, cellular and antibody-mediated immune responses. Endocrinology. 142: 464-76. PMID 11145611 DOI: 10.1210/Endo.142.1.7898  0.552
2000 Brown O, Cowen RL, Preston CM, Castro MG, Lowenstein PR. Subcellular post-transcriptional targeting: delivery of an intracellular protein to the extracellular leaflet of the plasma membrane using a glycosyl-phosphatidylinositol (GPI) membrane anchor in neurons and polarised epithelial cells. Gene Therapy. 7: 1947-53. PMID 11127583 DOI: 10.1038/Sj.Gt.3301325  0.52
2000 Smith-Arica JR, Morelli AE, Larregina AT, Smith J, Lowenstein PR, Castro MG. Cell-type-specific and regulatable transgenesis in the adult brain: adenovirus-encoded combined transcriptional targeting and inducible transgene expression. Molecular Therapy : the Journal of the American Society of Gene Therapy. 2: 579-87. PMID 11124058 DOI: 10.1006/Mthe.2000.0215  0.569
2000 Gerdes CA, Castro MG, Löwenstein PR. Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 2: 330-8. PMID 11020348 DOI: 10.1006/Mthe.2000.0140  0.417
2000 Castro MG, Cowen R, Smith-Arica J, Williams J, Ali S, Windeatt S, Gonzalez-Nicolini V, Maleniak T, Lowenstein PR. Gene therapy strategies for intracranial tumours: glioma and pituitary adenomas. Histology and Histopathology. 15: 1233-52. PMID 11005248 DOI: 10.14670/Hh-15.1233  0.568
2000 Southgate TD, Windeatt S, Smith-Arica J, Gerdes CA, Perone MJ, Morris I, Davis JR, Klatzmann D, Löwenstein PR, Castro MG. Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vectors in vitro and in vivo in normal and estrogen/sulpiride-induced hyperplastic anterior pituitaries. Endocrinology. 141: 3493-505. PMID 10965923 DOI: 10.1210/Endo.141.9.7639  0.453
2000 Carrington LM, Southgate T, Saxby LA, Abul-Hassan K, Maleniak TC, Castro MG, Boulton ME. Adenovirus-mediated gene transfer to human lens epithelial cells in organ culture. Journal of Cataract and Refractive Surgery. 26: 887-92. PMID 10889436 DOI: 10.1016/S0886-3350(00)00325-4  0.341
2000 Thomas CE, Schiedner G, Kochanek S, Castro MG, Löwenstein PR. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proceedings of the National Academy of Sciences of the United States of America. 97: 7482-7. PMID 10840055 DOI: 10.1073/Pnas.120474397  0.402
2000 Turvey SE, Gonzalez-Nicolini V, Kingsley CI, Larregina AT, Morris PJ, Castro MG, Lowenstein PR, Wood KJ. Fas ligand-transfected myoblasts and islet cell transplantation. Transplantation. 69: 1972-6. PMID 10830245 DOI: 10.1097/00007890-200005150-00043  0.538
2000 Cowsill C, Southgate TD, Morrissey G, Dewey RA, Morelli AE, Maleniak TC, Forrest Z, Klatzmann D, Wilkinson GW, Löwenstein PR, Castro MG. Central nervous system toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidine kinase: reduced cytotoxicity of a truncated HSV1-TK. Gene Therapy. 7: 679-85. PMID 10800091 DOI: 10.1038/Sj.Gt.3301147  0.406
2000 Guillot C, Mathieu P, Coathalem H, Le Mauff B, Castro MG, Tesson L, Usal C, Laumonier T, Brouard S, Soulillou JP, Lowenstein PR, Cuturi MC, Anegon I. Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA4Ig expression. Journal of Immunology (Baltimore, Md. : 1950). 164: 5258-68. PMID 10799887 DOI: 10.4049/Jimmunol.164.10.5258  0.536
2000 Windeatt S, Southgate TD, Dewey RA, Bolognani F, Perone MJ, Larregina AT, Maleniak TC, Morris ID, Goya RG, Klatzmann D, Löwenstein PR, Castro MG. Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas. The Journal of Clinical Endocrinology and Metabolism. 85: 1296-305. PMID 10720079 DOI: 10.1210/Jcem.85.3.6482  0.398
2000 Stone D, David A, Bolognani F, Lowenstein PR, Castro MG. Viral vectors for gene delivery and gene therapy within the endocrine system. The Journal of Endocrinology. 164: 103-18. PMID 10657846 DOI: 10.1677/Joe.0.1640103  0.545
1999 Castro MG, Davis JR, Xiong W, Lowenstein PR. Recent developments in gene therapy: applications for the treatment of pituitary tumours. Bailliã¨Re's Best Practice & Research. Clinical Endocrinology & Metabolism. 13: 431-49. PMID 10909434 DOI: 10.1053/Beem.1999.0035  0.519
1999 Southgate TD, Bain D, Fairbanks LD, Morelli AE, Larregina AT, Simmonds HA, Castro MG, Löwenstein PR. Adenoviruses encoding HPRT correct biochemical abnormalities of HPRT-deficient cells and allow their survival in negative selection medium. Metabolic Brain Disease. 14: 205-21. PMID 10850548 DOI: 10.1023/A:1020728924026  0.383
1999 Lowenstein PR, Cowen R, Thomas C, Castro MG. The basic science of brain-tumour gene therapy. Biochemical Society Transactions. 27: 873-81. PMID 10830120 DOI: 10.1042/Bst0270873  0.527
1999 Castro MG, Windeatt S, Smith-Arica J, Lowenstein PR. Cell-type specific expression in the pituitary: physiology and gene therapy. Biochemical Society Transactions. 27: 858-63. PMID 10830117 DOI: 10.1042/Bst0270858  0.555
1999 Davis JR, Lowenstein PR, McNeilly AS, Castro MG. Gene therapy for pituitary tumours. Endocrine-Related Cancer. 6: 475-81. PMID 10730901 DOI: 10.1677/Erc.0.0060475  0.508
1999 Tomasec P, Preston CM, Linton EA, Ahmed I, Lowenstein PR, Castro MG. Generation of a recombinant herpes simplex virus type 1 expressing the rat corticotropin- releasing hormone precursor: endoproteolytic processing, intracellular targeting and biological activity. Neuroendocrinology. 70: 439-50. PMID 10657737 DOI: 10.1159/000054506  0.536
1999 Dewey RA, Morrissey G, Cowsill CM, Stone D, Bolognani F, Dodd NJ, Southgate TD, Klatzmann D, Lassmann H, Castro MG, Löwenstein PR. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nature Medicine. 5: 1256-63. PMID 10545991 DOI: 10.1038/15207  0.424
1999 Lowenstein PR, Thomas CE, Castro MG. Politically correct gene therapy? A "clean environment" improves gene delivery to the brain! Gene Therapy. 6: 463-4. PMID 10476205 DOI: 10.1038/Sj.Gt.3300917  0.529
1999 Ambar BB, Frei K, Malipiero U, Morelli AE, Castro MG, Lowenstein PR, Fontana A. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Human Gene Therapy. 10: 1641-8. PMID 10428209 DOI: 10.1089/10430349950017644  0.56
1999 Morelli AE, Larregina AT, Smith-Arica J, Dewey RA, Southgate TD, Ambar B, Fontana A, Castro MG, Lowenstein PR. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. The Journal of General Virology. 80: 571-83. PMID 10091995 DOI: 10.1099/0022-1317-80-3-571  0.555
1999 Cartmell T, Southgate T, Rees GS, Castro MG, Lowenstein PR, Luheshi GN. Interleukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 19: 1517-23. PMID 9952427 DOI: 10.1523/Jneurosci.19-04-01517.1999  0.549
1999 Castro MG. Gene therapy strategies for the treatment of pituitary tumours. Journal of Molecular Endocrinology. 22: 9-18. PMID 9924175 DOI: 10.1677/Jme.0.0220009  0.4
1999 Korner J, Chua SC, Williams JA, Leibel RL, Wardlaw SL, Jacobsson G, Bean AJ, Meister B, Kümpfel T, Bergh FT, Friess E, Uhr M, Yassouridis A, Trenkwalder C, Holsboer F, ... ... Castro MG, et al. Contents Vol. 70, 1999 Neuroendocrinology. 70: 471-473. DOI: 10.1159/000054512  0.395
1999 Korner J, Chua SC, Williams JA, Leibel RL, Wardlaw SL, Jacobsson G, Bean AJ, Meister B, Kümpfel T, Bergh FT, Friess E, Uhr M, Yassouridis A, Trenkwalder C, Holsboer F, ... ... Castro MG, et al. Subject Index Vol. 70, 1999 Neuroendocrinology. 70: 469-470. DOI: 10.1159/000054511  0.4
1999 Castro M. CELL TYPE SPECIFIC EXPRESSION IN THE PITUITARY: PHYSIOLOGY AND CANCER TREATMENT Biochemical Society Transactions. 27: A139-A139. DOI: 10.1042/Bst027A139A  0.304
1998 Lowenstein PR, Southgate TD, Smith-Arica JR, Smith J, Castro MG. Gene therapy for inherited neurological disorders: towards therapeutic intervention in the Lesch-Nyhan syndrome. Progress in Brain Research. 117: 485-501. PMID 9932427 DOI: 10.1016/S0079-6123(08)64034-0  0.539
1998 Perone MJ, Murray CA, Brown OA, Gibson S, White A, Linton EA, Perkins AV, Lowenstein PR, Castro MG. Procorticotrophin-releasing hormone: endoproteolytic processing and differential release of its derived peptides within AtT20 cells. Molecular and Cellular Endocrinology. 142: 191-202. PMID 9783915 DOI: 10.1016/S0303-7207(98)00104-X  0.486
1998 Perone MJ, Windeatt S, Morrison E, Shering A, Tomasec P, Linton E, Lowenstein PR, Castro MG. Intracellular retention of the corticotrophin-releasing hormone (CRH) precursor within COS-7 cells. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 46: 1193-7. PMID 9742076 DOI: 10.1177/002215549804601012  0.485
1998 Goya RG, Rowe J, Sosa YE, Tomasec P, Lowenstein PR, Castro MG. Use of recombinant herpes simplex virus type 1 vectors for gene transfer into tumour and normal anterior pituitary cells. Molecular and Cellular Endocrinology. 139: 199-207. PMID 9705088 DOI: 10.1016/S0303-7207(98)00059-8  0.547
1998 Cahusac PM, Castro MG, Robertson L, Lowenstein PR. Electrophysiological evidence against a neurotransmitter role of corticotropin-releasing hormone (CRH) in primary somatosensory cortex. Brain Research. 793: 73-8. PMID 9630525 DOI: 10.1016/S0006-8993(98)00162-0  0.461
1998 Larregina AT, Morelli AE, Dewey RA, Castro MG, Fontana A, Lowenstein PR. FasL induces Fas/Apo1-mediated apoptosis in human embryonic kidney 293 cells routinely used to generate E1-deleted adenoviral vectors. Gene Therapy. 5: 563-8. PMID 9614583 DOI: 10.1038/Sj.Gt.3300615  0.53
1997 Brown OA, Santer RM, Shering AF, Larregina AT, Morelli AE, Southgate TD, Castro MG, Lowenstein PR. Gene transfer into enteric neurons of the rat small intestine in organ culture using a replication defective recombinant herpes simplex virus type 1 (HSV1) vector, but not recombinant adenovirus vectors. Gene Therapy. 4: 331-8. PMID 9176519 DOI: 10.1038/Sj.Gt.3300383  0.527
1997 Castro MG, Goya RG, Sosa YE, Rowe J, Larregina A, Morelli A, Lowenstein PR. Expression of transgenes in normal and neoplastic anterior pituitary cells using recombinant adenoviruses: long term expression, cell cycle dependency, and effects on hormone secretion. Endocrinology. 138: 2184-94. PMID 9112418 DOI: 10.1210/Endo.138.5.5134  0.584
1997 Castro MG, Morrison E. Post-translational processing of proopiomelanocortin in the pituitary and in the brain. Critical Reviews in Neurobiology. 11: 35-57. PMID 9093813 DOI: 10.1615/Critrevneurobiol.V11.I1.30  0.302
1997 Stewart K, Brown OA, Morelli AE, Fairbairn LJ, Lashford LS, Cooper A, Hatton CE, Dexter TM, Castro MG, Lowenstein PR. Uptake of alpha-(L)-iduronidase produced by retrovirally transduced fibroblasts into neuronal and glial cells in vitro. Gene Therapy. 4: 63-75. PMID 9068797 DOI: 10.1038/Sj.Gt.3300364  0.499
1997 Shering AF, Bain D, Stewart K, Epstein AL, Castro MG, Wilkinson GW, Lowenstein PR. Cell type-specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors. The Journal of General Virology. 78: 445-59. PMID 9018068 DOI: 10.1099/0022-1317-78-2-445  0.554
1996 Walker VE, Rowe JM, Castro MG, Jacob TJ. Gene transfer into cultured bovine ciliary epithelial cells using adenovirus vectors. Biochemical Society Transactions. 24: 423S. PMID 8878967 DOI: 10.1042/Bst024423S  0.324
1996 Castro MG, Morrison E, Perone MJ, Brown OA, Murray CA, Ahmed I, Perkins AV, Europe-Finner G, Lowenstein PR, Linton EA. Corticotrophin-releasing hormone receptor type 1: generation and characterization of polyclonal antipeptide antibodies and their localization in pituitary cells and cortical neurones in vitro. Journal of Neuroendocrinology. 8: 521-31. PMID 8843021 DOI: 10.1046/J.1365-2826.1996.04866.X  0.499
1995 Lowenstein PR, Bain D, Shering AF, Wilkinson GW, Castro MG. Cell type-specific expression from viral promoters within replication-deficient adenovirus recombinants in primary neocortical cultures. Restorative Neurology and Neuroscience. 8: 37-9. PMID 21551803 DOI: 10.3233/Rnn-1995-81209  0.52
1995 Castro MG, Rowe JM, Murray CA, Tomasec P, Shering AF, Linton EA, Ahmed I, Lowenstein PR. Generation and characterization of an antiserum reactive with a proteolytic processing site within rat procorticotrophin-releasing hormone. Neuropeptides. 29: 183-92. PMID 8584136 DOI: 10.1016/0143-4179(95)90060-8  0.471
1995 Castro MG, Morrison E, Tomasec P, Linton EA, Lowenstein PR. Co-localisation of autoimmune antibodies specific for double stranded DNA with procorticotrophin-releasing hormone within the nucleus of stably transfected CHO-K1 cells. Cell and Tissue Research. 282: 367-76. PMID 8581931 DOI: 10.1007/Bf00318869  0.478
1995 Morrison E, Tomasec P, Linton EA, Lowry PJ, Lowenstein PR, Castro MG. Expression of biologically active procorticotrophin-releasing hormone (proCRH) in stably transfected CHO-K1 cells: characterization of nuclear proCRH. Journal of Neuroendocrinology. 7: 263-72. PMID 7647768 DOI: 10.1111/J.1365-2826.1995.Tb00756.X  0.512
1995 Lowenstein PR, Shering AF, Morrison E, Tomasec P, Bain D, Jacob TJ, Wu J, Prescott A, Castro MG. Synaptogenesis and distribution of presynaptic axonal varicosities in low density primary cultures of neocortex: an immunocytochemical study utilizing synaptic vesicle-specific antibodies, and an electrophysiological examination utilizing whole cell recording. Journal of Neurocytology. 24: 301-17. PMID 7643134 DOI: 10.1007/Bf01186542  0.441
1995 Lowenstein PR, Fournel S, Bain D, Tomasec P, Clissold PM, Castro MG, Epstein AL. Simultaneous detection of amplicon and HSV-1 helper encoded proteins reveals that neurons and astrocytoma cells do express amplicon-borne transgenes in the absence of synthesis of virus immediate early proteins. Brain Research. Molecular Brain Research. 30: 169-75. PMID 7609639 DOI: 10.1016/0169-328X(95)00002-A  0.51
1994 Bain D, Wilkinson GW, Preston CM, Castro MG, Lowenstein PR. Adenovirus vectors to transfer genes into neurones: implications for gene therapy of neurological disorders. Gene Therapy. 1: S68. PMID 8542414  0.44
1994 Tomasec P, Lowenstein PR, Morrison E, Hodge P, Linton EA, Perkins A, Lowry PJ, Castro MG. Use of gene transfer to study post-translational modifications of neuropeptides in cell lines. Gene Therapy. 1: S64. PMID 8542410  0.433
1994 Morrison E, Lowenstein PR, Hodge P, Linton E, Lowry PJ, Corredoira Y, Castro MG. Nuclear and cytoplasmic localisation of procorticotrophin releasing hormone in transfected CHO-K1 cells. Gene Therapy. 1: S62. PMID 8542408  0.389
1994 Lowenstein PR, Bain D, Morrison EE, Preston CM, Clissold P, Fournel S, Epstein A, Castro MG. HSV1 vectors to study protein targeting in neurones: are glycosyl-phosphatidylinositol anchors polarized targeting signals in neurones? Gene Therapy. 1: S32-5. PMID 8542390  0.412
1994 Castro MG, Hodge P, Corredoira YA, Morrison E, Tomasec P, Murray CA, Lowenstein PR. Neuropeptide gene transfer into neuronal and glial cell lines. Gene Therapy. 1: S15-8. PMID 8542384  0.472
1994 Lowenstein PR, Morrison EE, Bain D, Shering AF, Banting G, Douglas P, Castro MG. Polarized distribution of the trans-Golgi network marker TGN38 during the in vitro development of neocortical neurons: effects of nocodazole and brefeldin A. The European Journal of Neuroscience. 6: 1453-65. PMID 8000569 DOI: 10.1111/J.1460-9568.1994.Tb01007.X  0.456
1994 Lowenstein PR, Morrison EE, Bain D, Hodge P, Preston CM, Clissold P, Stow ND, McKee TA, Castro MG. Use of recombinant vectors derived from herpes simplex virus 1 mutant tsK for short-term expression of transgenes encoding cytoplasmic and membrane anchored proteins in postmitotic polarized cortical neurons and glial cells in vitro. Neuroscience. 60: 1059-77. PMID 7936206 DOI: 10.1016/0306-4522(94)90283-6  0.512
1994 Lowenstein PR, Fournel S, Bain D, Tomasec P, Clissold P, Castro MG, Epstein AL. Herpes simplex virus 1 (HSV-1) helper co-infection affects the distribution of an amplicon encoded protein in glia. Neuroreport. 5: 1625-30. PMID 7819534 DOI: 10.1097/00001756-199408150-00021  0.482
1994 Castro M, Morrison E, Tomasec P, Lowenstein P. Biosynthesis and nuclear translocation of the proneuropeptide procorticotrophin-releasing hormone (proCRH) Neuropeptides. 26: 9. DOI: 10.1016/0143-4179(94)90156-2  0.425
1993 Ringan NS, Grayson L, Lowenstein PR, Linton EA, Lowry PJ, Castro MG. Prediction of protein antigenic sites in human corticotrophin-releasing hormone precursor. Comparative Biochemistry and Physiology. B, Comparative Biochemistry. 104: 521-9. PMID 8482078 DOI: 10.1016/0305-0491(93)90277-C  0.459
1993 Morrison E, Lowenstein PR, Tomasec P, Hodge P, Linton E, Devine J, Lowry PJ, Castro MG. Intracellular compartmentalisation of procorticotrophin releasing hormone. Biochemical Society Transactions. 21: 47S. PMID 8449331 DOI: 10.1042/Bst021047S  0.428
1993 Lowenstein PR, Morrison E, Hodge P, Tomasec P, Shering AF, Stow ND, Preston CM, James JL, Castro MG. Polarity development and synaptogenesis in low density primary cultures of neocortex. Use of herpes simplex virus-1 vectors to transfer genes into postmitotic neurons. Biochemical Society Transactions. 21: 14S. PMID 8383604 DOI: 10.1042/Bst021014S  0.463
1993 Lowenstein PR, Morrison E, Douglas P, Preston CM, Clissold P, Banting G, Stow ND, Castro MG. Neocortical neuronal polarity: targeting of a foreign protein linked to a glycosyl-phosphatidylinositol (GPI) anchor in postmitotic neurons and polarized distribution of a marker of the trans-Golgi network (TGN 38). Biochemical Society Transactions. 21: 117S. PMID 8359373 DOI: 10.1042/Bst021117S  0.433
1993 Morrison E, Hodge P, Tomasec P, Lowenstein PR, Linton EA, Lowry PJ, Castro MG. Nuclear localisation of corticotrophin releasing hormone (CRH) in transfected CHO-K1 cells. Biochemical Society Transactions. 21: 318S. PMID 8224463 DOI: 10.1042/Bst021318S  0.461
1992 Castro MG, Lowry PJ, Lowenstein PR. Antibodies to neuropeptide precursors expressed as fusion proteins in E. coli. Their use to examine neuropeptide biosynthetic pathways, intracellular trafficking and physiological activities. The International Journal of Biochemistry. 24: 847-60. PMID 1612176 DOI: 10.1016/0020-711X(92)90089-J  0.465
1991 Castro M, Lowenstein P, Glynn B, Hannah M, Linton E, Lowry P. Post-translational processing and regulated release of corticotropin-releasing hormone (CRH) in AtT20 cells expressing the human proCRH gene Biochemical Society Transactions. 19: 246S. PMID 1664370 DOI: 10.1042/Bst019246S  0.494
1990 Castro MG, Lowenstein PR, Saphier PW, Linton EA, Lowry PJ. The use of inclusion bodies, isolated from Escherichia coli expressing corticotrophin-releasing hormone precursor, to raise specific antibodies against the neuropeptide moiety. Journal of Molecular Endocrinology. 5: 221-30. PMID 2126928 DOI: 10.1677/Jme.0.0050221  0.462
1988 Loh YP, Castro MG, Zeng FJ, Patel-Vaidya U. Presence of pro-vasopressin mRNA, neurophysin and arginine vasopressin in mouse anterior pituitary cells and the AtT-20 corticotrophic tumour cell line. Journal of Molecular Endocrinology. 1: 39-48. PMID 2855708 DOI: 10.1677/Jme.0.0010039  0.307
1984 Castro M, Estivariz F, Iturriza F. The regulation of the cortico-melanotrophic cell activity in aves—I. Evaluation and selection of in vitro systems for testing ACTH-releasing substances in the duck pituitary Comparative Biochemistry and Physiology Part a: Physiology. 79: 169-173. DOI: 10.1016/0300-9629(84)90727-8  0.304
Show low-probability matches.